var title_f16_63_17392="Defects in leukocyte adhesion deficiency disorders";
var content_f16_63_17392=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F73528&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F73528&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 570px\">",
"   <div class=\"ttl\">",
"    Leukocyte adhesion cascade",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 550px; height: 395px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_63_17392=[""].join("\n");
var outline_f16_63_17392=null;
var title_f16_63_17393="Patient information: Septic arthritis (The Basics)";
var content_f16_63_17393=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?32/50/33569\">",
"         Patient information: Sepsis in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?18/21/18769\">",
"         Patient information: Joint infection (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Septic arthritis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/septic-arthritis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H13207864\">",
"      <span class=\"h1\">",
"       What is septic arthritis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Septic arthritis is a condition that causes a painful, swollen, and fluid-filled joint. Septic arthritis is caused by an infection in the joint. This infection is usually caused by bacteria, but it can also be caused by other germs. The bacteria get into the joint in different ways. Most often, the bacteria travel to the joint through the blood from another part of the body.",
"     </p>",
"     <p>",
"      Septic arthritis sometimes leads to joint damage and long-term joint problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13207879\">",
"      <span class=\"h1\">",
"       What are the symptoms of septic arthritis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms usually start suddenly and can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Joint pain",
"       </li>",
"       <li>",
"        Joint swelling",
"       </li>",
"       <li>",
"        Warm skin around the joint",
"       </li>",
"       <li>",
"        Trouble moving the joint",
"       </li>",
"       <li>",
"        Fever",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Septic arthritis usually affects only 1 joint, but sometimes it affects more than 1 joint. Joints commonly involved are the knee, wrist, ankle, and hip.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13207894\">",
"      <span class=\"h1\">",
"       Is there a test for septic arthritis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Tests for septic arthritis include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Lab tests on a sample of fluid from the joint &ndash; Usually, the doctor can use a needle and syringe to get a sample of fluid. But sometimes the doctor has to do surgery to get a sample of fluid. The fluid sample is sent to a lab for tests.",
"       </li>",
"       <li>",
"        Blood tests, called &ldquo;blood cultures,&rdquo; to check for bacteria in the blood",
"       </li>",
"       <li>",
"        An X-ray of the joint",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13207909\">",
"      <span class=\"h1\">",
"       How is septic arthritis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment for septic arthritis involves both:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Antibiotic medicines &ndash; These medicines kill the germs that are causing the infection. People usually get these medicines in their vein through a tube called an &ldquo;IV.&rdquo;",
"       </li>",
"       <li>",
"        Draining the fluid from the joint &ndash; Doctors can drain the fluid in different ways, depending on which joint is involved. Many times, they can use a needle and syringe to drain the fluid. But sometimes they need to do surgery to drain the fluid. If your joint keeps filling up with fluid, you might need to have the fluid drained more than once.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Your doctor might also have you work with a physical therapist (exercise expert). The physical therapist can show you exercises to prevent joint problems and keep your joint from getting too stiff.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13207933\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/50/33569?source=see_link\">",
"       Patient information: Sepsis in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?18/21/18769?source=see_link\">",
"       Patient information: Joint infection (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?16/63/17393?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83255 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.97.94.19-A044F949FA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_63_17393=[""].join("\n");
var outline_f16_63_17393=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13207864\">",
"      What is septic arthritis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13207879\">",
"      What are the symptoms of septic arthritis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13207894\">",
"      Is there a test for septic arthritis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13207909\">",
"      How is septic arthritis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13207933\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/21/18769?source=related_link\">",
"      Patient information: Joint infection (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/50/33569?source=related_link\">",
"      Patient information: Sepsis in adults (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_63_17394="Large right pneumothorax";
var content_f16_63_17394=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51728&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51728&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 567px\">",
"   <div class=\"ttl\">",
"    Posterior-anterior (PA) chest radiographs showing a large right pneumothorax",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 547px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The left-hand image represents a conventional radiograph. A large right pneumothorax is demonstrated. The visceral pleural line is marked by red arrows. The lack of vascular and pulmonary markings in the periphery should be noted. The right-hand image represents the negative image of the film on the left. The pneumothorax is more clearly seen in this view.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_63_17394=[""].join("\n");
var outline_f16_63_17394=null;
var title_f16_63_17395="Pedicle advancement ab flap";
var content_f16_63_17395=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F81818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F81818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Abdominal pedicle flap and burned hand.",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A burned hand is placed in a pedicle abdominal flap for coverage of exposed joints and tendons of the digits. The hand will remain in place until the wound is revascularized, approximately two to three weeks. The pedicle will then be severed and the wounds closed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_63_17395=[""].join("\n");
var outline_f16_63_17395=null;
var title_f16_63_17396="Non-small cell lung cancer treatment; stage IV cancer";
var content_f16_63_17396=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Non-small cell lung cancer treatment; stage IV cancer (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?16/63/17396/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/63/17396/contributors\" id=\"au5021\">",
"       Rogerio C Lilenbaum, MD, FACP",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?16/63/17396/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/63/17396/contributors\" id=\"se4114\">",
"       James R Jett, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?16/63/17396/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/63/17396/contributors\" id=\"de7369\">",
"       Michael E Ross, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?16/63/17396?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Stage IV non-small cell lung cancer includes cancers that have spread to areas beyond the chest, like the brain (",
"     <a class=\"graphic graphic_figure graphicRef74377 \" href=\"UTD.htm?6/8/6278\">",
"      figure 1",
"     </a>",
"     ). Stage IV cancer also includes people who have a fluid collection around the lung (called a malignant pleural effusion) caused by the cancer.",
"    </p>",
"    <p>",
"     Stage IV non-small cell lung cancer cannot be cured, but treatment can reduce pain, ease breathing, and extend and improve quality of life.",
"    </p>",
"    <p>",
"     Treatment of stage I to III non-small cell lung cancer is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/22/41314?source=see_link\">",
"      \"Patient information: Non-small cell lung cancer treatment; stage I to III cancer (Beyond the Basics)\"",
"     </a>",
"     .) More detailed information about stage IV non-small cell lung cancer is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/57/21401?source=see_link\">",
"      \"Overview of the treatment of advanced non-small cell lung cancer\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H761923624\">",
"     <span class=\"h1\">",
"      PERSONALIZED TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     An improved understanding of the biology of non-small cell lung cancer has led to the recognition that there are a number of different forms of non-small cell lung cancer and that certain treatments are more effective in one type and other treatments are more effective in others. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14809?source=see_link\">",
"      \"Personalized, genotype-directed therapy for advanced non-small cell lung cancer\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     In many cases, very specific molecular abnormalities have been found, and these identify the different types of non-small cell lung cancer. These can be identified by an analysis of the DNA from the tumor by looking for specific changes (mutations). New treatments developed to specifically address these abnormalities are referred to as targeted therapy. When such changes are not found, a more general approach, chemotherapy, is usually preferred. Surgery might be an option in some patients if the cancer has spread to a single place outside the lung.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      TARGETED THERAPY",
"     </span>",
"    </p>",
"    <p>",
"     Targeted therapy is the name for anticancer treatments that interfere with how a cancer grows and spreads when a very specific abnormality is present. These treatments work in a different way than standard chemotherapy. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14809?source=see_link\">",
"      \"Personalized, genotype-directed therapy for advanced non-small cell lung cancer\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The decision about which targeted therapy, if any, to use depends on your particular cancer. Generally, a sample of your tumor that was obtained by surgery or biopsy is analyzed in the laboratory to make this decision. When such an abnormality is present, the likelihood of a favorable response to treatment is much higher than with older forms of treatment such as chemotherapy.",
"    </p>",
"    <p>",
"     Testing can be done to see if your cancer belongs to one of the categories that is likely to respond to targeted therapy.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Epidermal growth factor receptor (EGFR) mutations &ndash; When the epidermal growth factor receptor contains a particular abnormality (mutation), this change can stimulate growth and spread of the tumor. Erlotinib (Tarceva) and gefitinib (Iressa) are targeted chemotherapy medicines that block the growth of the tumor in this situation. If an abnormality in EGFR is found, targeted therapy is generally used instead of standard chemotherapy. The most common side effects of erlotinib and gefitinib are skin rash and diarrhea. Gefitinib is not available in the United States. (See",
"       <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31816?source=see_link\">",
"        \"Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Anaplastic lymphoma kinase (ALK) gene abnormalities &ndash; A fusion (combination) of the ALK gene with another gene such as EML can drive the growth of some non-small cell lung cancers. Crizotinib (Xalkori) is a targeted medicine that blocks the cancer stimulus caused by this ALK abnormality. Crizotinib is more effective than standard chemotherapy in patients with lung cancer containing this abnormality, and thus crizotinib is generally recommended as the initial therapy instead of standard chemotherapy in this situation. Crizotinib is generally well tolerated, and the most common side effects of crizotinib are mild changes in vision and nausea, vomiting, and diarrhea. (See",
"       <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40440?source=see_link&amp;anchor=H11#H11\">",
"        \"Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer\", section on 'Crizotinib'",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Other specific abnormalities, based upon an analysis of the genes in tumors, are being studied and may lead to specific treatments. In some cases, you may want to consider participating in a clinical trial of new agents, if your tumor contains one of these abnormalities.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     If your initial treatment with a targeted agent does not work, or if you initially respond and then your disease progresses, your doctor may recommend treatment with chemotherapy.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H761923659\">",
"     <span class=\"h1\">",
"      CHEMOTHERAPY",
"     </span>",
"    </p>",
"    <p>",
"     When no specific abnormality is identified, chemotherapy is generally recommended to treat stage IV non-small cell lung cancer. Chemotherapy can often slow or stop the growth of tumors at least temporarily.",
"    </p>",
"    <p>",
"     Chemotherapy is given to slow or stop the growth of cancer cells. It is not given every day but instead is given in cycles. A cycle of chemotherapy (typically about 21 days) refers to the time it takes to give the treatment and then allow the body to recover from the side effects of the medicines. Your healthcare provider can describe which chemotherapy drugs will be needed. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34666?source=see_link\">",
"      \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Most treatments involve a combination (regimen) of two chemotherapy drugs. The most commonly used regimens include either cisplatin (Platinol) or carboplatin (Paraplatin); this is combined with one of several other drugs (such as pemetrexed [Alimta], paclitaxel [Taxol], docetaxel [Taxotere], gemcitabine [Gemzar], vinorelbine [Navelbine]).",
"    </p>",
"    <p>",
"     Most of the drugs are given into a vein (intravenous, IV) once every three weeks. In some cases, your doctor will recommend combining these chemotherapy drugs with either bevacizumab (Avastin), a medicine that blocks a protein called vascular endothelial growth factor (VEGF), or with cetuximab (Erbitux), which targets the epidermal growth factor receptor.",
"    </p>",
"    <p>",
"     Four to six cycles of chemotherapy are usually recommended, depending upon your response to treatment. In many cases, your doctor may recommend continuation of treatment with one drug after the four cycles of chemotherapy, if you have had a favorable response to the initial treatment.",
"    </p>",
"    <p>",
"     If your initial chemotherapy treatment does not work, or if you initially respond and then have progressive disease, your doctor may recommend treatment with other chemotherapy medications or a targeted agent such as erlotinib.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H761923686\">",
"     <span class=\"h2\">",
"      Side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;The most serious side effect of chemotherapy is a temporary drop in your blood count. This can increase your risk of developing an infection. Blood counts typically fall 7 to 14 days after the chemotherapy is given. During this time, you should call your doctor or nurse immediately if you develop chills or have a fever (temperature higher than 100.4&ordm;F or 38&ordm;C).",
"    </p>",
"    <p>",
"     Other possible side effects of chemotherapy include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Temporary hair loss",
"      </li>",
"      <li>",
"       Numbness in the fingers and toes (called neuropathy)",
"      </li>",
"      <li>",
"       Nausea and vomiting",
"      </li>",
"      <li>",
"       Skin rash",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H761923693\">",
"     <span class=\"h2\">",
"      Treatment for older people and those who are ill",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some people are not healthy enough to have a chemotherapy regimen with two drugs as described above. This might include people who are older or who have another serious illness. In this case, treatment with one chemotherapy medicine (rather than two) or with a targeted therapy (see",
"     <a class=\"local\" href=\"#H5\">",
"      'Targeted therapy'",
"     </a>",
"     above) may be an option. This type of treatment can prolong survival and improve quality of life. The side effects of one chemotherapy medicine are not as severe as when two are used.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      MANAGEMENT OF METASTASES IN NON-SMALL CELL LUNG CANCER",
"     </span>",
"    </p>",
"    <p>",
"     The brain, the bones, and the area around the lungs (the pleural space) are common places for cancer to spread in people with non-small cell lung cancer. Cancer that has spread to the brain or bones is called metastatic lung cancer, not brain cancer or bone cancer.",
"    </p>",
"    <p>",
"     In some cases, certain areas of spread require particular treatment directed toward the metastases.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Malignant pleural effusion",
"     </span>",
"     &nbsp;&mdash;&nbsp;A pleural effusion is a collection of fluid in the chest that is located in the pleural space, a pocket between the lung and the tissues of the chest wall (",
"     <a class=\"graphic graphic_figure graphicRef74377 \" href=\"UTD.htm?6/8/6278\">",
"      figure 1",
"     </a>",
"     ). This space is normally empty, although it can accumulate fluid in people with advanced lung cancer. The fluid pushes against the lung, compressing it and preventing the lung from fully expanding when breathing. Thus, the most common symptom of a pleural effusion is shortness of breath.",
"    </p>",
"    <p>",
"     In most people with advanced lung cancer, the pleural effusion is caused by the cancer. This is called a malignant pleural effusion. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/6/13416?source=see_link\">",
"      \"Management of malignant pleural effusions\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Treatment of the pleural effusion is usually recommended for people who develop shortness of breath. Shortness of breath often worsens as more fluid accumulates.",
"    </p>",
"    <p>",
"     The simplest way to treat a pleural effusion is to insert a small tube (a catheter) into the space around the lung and allow the fluid to drain out. Afterward, the catheter is removed. This is called a thoracentesis. Thoracentesis can usually be done in the office or hospital room using local anesthesia.",
"    </p>",
"    <p>",
"     If the fluid reaccumulates quickly, meaning that you need another thoracentesis in less than one month, a more aggressive treatment might be recommended. This includes a catheter that is left in place (a tunneled catheter) or using a substance to block the build-up of fluid (called pleurodesis).",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Tunneled catheter &mdash; Some people are treated with a catheter that is left in the pleural space and connected to a container. This is called a tunneled catheter. The patient (or a family member) uses a vacuum bottle to drain the fluid once a day or as needed. The catheter is usually inserted during a day surgery procedure. It is left in place for several weeks or months, as long as the fluid continues to drain. The advantage of a catheter over other treatments is that it allows the patient and their doctors to manage the fluid collection out of the hospital.",
"      </li>",
"      <li>",
"       Pleurodesis &mdash; Another option for treating a malignant effusion is called chemical pleurodesis. This involves draining the fluid and then applying a substance (usually talcum powder) to the surface of the lung, which helps prevent the fluid from collecting again. This treatment is usually done in the hospital and requires a three- to five-day stay. It may be associated with temporary pain and fever for a few days.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Brain metastases",
"     </span>",
"     &nbsp;&mdash;&nbsp;Symptoms of brain metastases can include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Headache (often in the morning)",
"      </li>",
"      <li>",
"       Weakness",
"      </li>",
"      <li>",
"       Trouble thinking clearly",
"      </li>",
"      <li>",
"       Seizures (convulsions)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     If your doctor is concerned about brain metastasis, he or she will order a magnetic resonance imaging (MRI) study or CT scan. Treatments for brain metastases include radiation therapy and medicines to reduce brain swelling (steroids).",
"    </p>",
"    <p>",
"     People who have one or a small number of metastases in the brain are sometimes offered more aggressive treatment. This might include surgery to remove tumor(s) in the brain. Stereotactic radiosurgery (also called the gamma knife) is an alternative to surgery in selected patients. Stereotactic radiosurgery uses high doses of radiation in a small area given in small number of treatments. Both surgery and stereotactic radiosurgery are often combined with radiation therapy to the entire brain to prevent the regrowth of the cancer in the brain. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6057?source=see_link\">",
"      \"Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Bone metastases",
"     </span>",
"     &nbsp;&mdash;&nbsp;Bone metastases, the spread of lung cancer to one or more bones, can cause pain or fractures. There are several options for treating bone metastases: targeted therapy, chemotherapy, radiation therapy, and a medicine called a bisphosphonate.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Targeted therapy or chemotherapy can often shrink or slow the growth of bone metastases, since these medicines act throughout the body (see",
"       <a class=\"local\" href=\"#H5\">",
"        'Targeted therapy'",
"       </a>",
"       above and",
"       <a class=\"local\" href=\"#H761923659\">",
"        'Chemotherapy'",
"       </a>",
"       above).",
"      </li>",
"      <li>",
"       Radiation therapy can reduce bone pain caused by metastases. This treatment is a good option for people with severe bone pain caused by metastasis in one or a limited number of areas. The treatment usually begins to relieve pain within one week after treatment. The treatment is given in one or a few doses, similar to having an X-ray. (See",
"       <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33924?source=see_link\">",
"        \"Radiation therapy for the management of painful bone metastases\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Medicine (either a bisphosphonate or denosumab) might be used to prevent bone-metastasis-related problems, like fractures and bone loss. If your caregiver recommends this treatment, you should have any important dental work done first. There is a risk of a serious problem in the jaw bone related to dental work done after treatment when these drugs are used to treat bone metastases. (See",
"       <a class=\"medical medical_review\" href=\"UTD.htm?13/18/13608?source=see_link\">",
"        \"Bisphosphonates and denosumab in patients with metastatic cancer\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H505249603\">",
"     <span class=\"h1\">",
"      PALLIATIVE CARE",
"     </span>",
"    </p>",
"    <p>",
"     Stage IV lung cancer cannot be cured. However, early integration of palliative care into the treatment of patients with advanced non-small cell lung cancer may improve quality of life. This can include assessment of physical and psychological needs and the goals for care.",
"    </p>",
"    <p>",
"     Deciding when to stop treating the cancer can be difficult and should involve the patient, family, friends, and the healthcare team. Ending cancer treatment does not mean ending care. Hospice care is frequently recommended when a person is unlikely to live longer than six months. Hospice care involves treatment of all aspects of a patient's and family's needs, including the physical (eg, pain relief), psychological, social, and spiritual aspects of suffering. This care can be given at home or in a nursing home or hospice facility and usually involves multiple care providers, including a doctor, registered nurse, nursing aide, a chaplain or religious leader, a social worker, and volunteers.",
"    </p>",
"    <p>",
"     These providers work together to meet the patient's and family's needs and significantly reduce their suffering. For more information about hospice, see",
"     <a class=\"external\" href=\"file://www.hospicenet.org/\">",
"      www.hospicenet.org",
"     </a>",
"     . (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32008?source=see_link\">",
"      \"Hospice: Philosophy of care and appropriate utilization in the United States\"",
"     </a>",
"     .).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      CLINICAL TRIALS",
"     </span>",
"    </p>",
"    <p>",
"     Progress in treating lung cancer requires that better treatments be identified through clinical trials, which are conducted all over the world. A clinical trial is a carefully controlled way to study the effectiveness of new treatments or new combinations of known therapies. Ask for more information about clinical trials, or read about clinical trials at:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://www.cancer.gov/clinicaltrials/\">",
"        www.cancer.gov/clinicaltrials/",
"       </a>",
"      </li>",
"      <li>",
"       <a class=\"external\" href=\"file://clinicaltrials.gov/\">",
"        file://clinicaltrials.gov/",
"       </a>",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1784940456\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5518465\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/34/35363?source=see_link\">",
"      Patient information: Lung cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/44/3779?source=see_link\">",
"      Patient information: Non-small cell lung cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/13/11475?source=see_link\">",
"      Patient information: Lung cancer screening (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5518473\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/22/41314?source=see_link\">",
"      Patient information: Non-small cell lung cancer treatment; stage I to III cancer (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/61/13273?source=see_link\">",
"      Overview of the initial evaluation, treatment and prognosis of lung cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/31/14841?source=see_link\">",
"      Diagnosis and staging of non-small cell lung cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22201?source=see_link\">",
"      Pathology of lung malignancies",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/57/21401?source=see_link\">",
"      Overview of the treatment of advanced non-small cell lung cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14809?source=see_link\">",
"      Personalized, genotype-directed therapy for advanced non-small cell lung cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31816?source=see_link\">",
"      Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40440?source=see_link\">",
"      Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34666?source=see_link\">",
"      Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/34/9768?source=see_link\">",
"      Advanced non-small cell lung cancer: Maintenance therapy after initial chemotherapy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36455?source=see_link\">",
"      Systemic therapy for advanced non-small cell lung cancer in elderly patients and patients with a poor performance status",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26199?source=see_link\">",
"      Systemic therapy for poor performance status patients with advanced non-small cell lung cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6057?source=see_link\">",
"      Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33924?source=see_link\">",
"      Radiation therapy for the management of painful bone metastases",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/18/13608?source=see_link\">",
"      Bisphosphonates and denosumab in patients with metastatic cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/6/13416?source=see_link\">",
"      Management of malignant pleural effusions",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32008?source=see_link\">",
"      Hospice: Philosophy of care and appropriate utilization in the United States",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Cancer Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;1-800-4-CANCER",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nci.nih.gov/\">",
"      www.nci.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Society of Clinical Oncology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.net/portal/site/patient\">",
"      www.cancer.net/portal/site/patient",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Comprehensive Cancer Network",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nccn.com/\">",
"      www.nccn.com",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Global Resource for Advancing Cancer Education (GRACE)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancergrace.org/lung\">",
"      www.cancerGRACE.org/lung",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Lung Cancer Alliance",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.lungcanceralliance.org/\">",
"      www.lungcanceralliance.org",
"     </a>",
"     )",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 1, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?16/63/17396?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f16_63_17396=[""].join("\n");
var outline_f16_63_17396=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H761923624\">",
"           PERSONALIZED TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           TARGETED THERAPY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H761923659\">",
"           CHEMOTHERAPY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           MANAGEMENT OF METASTASES IN NON-SMALL CELL LUNG CANCER",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H505249603\">",
"           PALLIATIVE CARE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           CLINICAL TRIALS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/8/6278\" title=\"figure 1\">",
"           Lung ca IV PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f16_63_17397="Isoflurane: Drug information";
var content_f16_63_17397=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"16\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Isoflurane: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?38/54/39780?source=see_link\">",
"    see \"Isoflurane: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F184696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Forane&reg;;",
"     </li>",
"     <li>",
"      Terrell&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F855043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Forane&reg;;",
"     </li>",
"     <li>",
"      Isoflurane USP",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F184729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      General Anesthetic, Inhalation",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F184700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Anesthesia:",
"     </b>",
"     Inhalation: Minimum alveolar concentration (MAC), the concentration at which 50% of patients do not respond to surgical incision, is 1.15% (44 years of age)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maintenance: With nitrous oxide: 1% to 2.5%; without nitrous oxide: 1.5% to 3.5%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     MAC is increased in the young and decreased in the elderly.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F184701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     MAC is decreased in the elderly.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16160040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16160041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F184683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, for inhalation: USP: 99.9 mL/100 mL (100 mL, 250 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Forane&reg;: USP: 99.9 mL/100 mL (100 mL, 250 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Terrell&trade;: USP: 99.9 mL/100 mL (100 mL, 250 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F184673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F184685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Via isoflurane-specific calibrated vaporizer",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F184684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maintenance of general anesthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Use of isoflurane for induction of general anesthesia is an FDA-labeled indication; however, it is not recommended clinically due to its irritant properties and unpleasant odor, which causes breath-holding or coughing.",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F7871700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intraoperative cardio- and neuro-protection (ischemic preconditioning)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F184734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Isoflurane may be confused with enflurane",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F184727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Potential safety issues exist for occupational exposure to inhaled anesthetic gases (primarily nitrous oxide). Although there are no documented adverse effects of chronic occupational exposure to halogenated anesthetic vapors, like isoflurane, some epidemiological studies suggest a link between these anesthetics and increased health problems (particularly spontaneous abortion). No conclusive relationship has been determined, but the National Institute for Occupational Safety and Health Administration (NIOSH) recommends no worker be exposed to &gt;2 ppm (ceiling concentrations) over a period of 1 hour. Precautions (eg, adequate ventilation, scavenging-systems, minimizing leaks/spills) can help to lessen any potential risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Frequency not defined:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, hypotension, myocardial depression, tachycardia (transient)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Mood changes (may persist for &le;6 days after administration), cognitive function decreased (may persist for &le;3 days after administration)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Cholesterol decreased, hyperglycemia, hyperkalemia (perioperative)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Ileus, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Leukocytosis (transient)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Hepatic dysfunction (mild to severe; rare), hepatitis (rare), alkaline phosphatase decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: BUN decreased, creatinine increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Respiratory depression/arrest, respiratory irritation (coughing, laryngospasms-related to induction)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Malignant hyperthermia, shivering",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Cardiac arrest, hepatic failure (rare), hepatic necrosis (rare)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F184688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to isoflurane or any component of the formulation; known or suspected genetic susceptibility to malignant hyperthermia",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F184676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular effects: Decrease in blood pressure is dose dependent due to peripheral vasodilation primarily in skin and muscle; cardiac output is maintained. May produce cardiac steal (due to coronary vasodilation) and reflex tachycardia, but does not depress cardiac conduction nor does it sensitize the myocardium to catecholamine-induced arrhythmias like halothane (not available in U.S.).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Decreased blood flow: May cause decrease in hepatic, renal and splenic blood flow.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatitis: Postoperative hepatic dysfunction and hepatitis have rarely been reported. Postmarketing reports of hepatic failure and necrosis have also been rarely associated with isoflurane.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: Use of inhaled anesthetics has been associated with rare cases of perioperative hyperkalemia; concomitant use of succinylcholine was associated with many of the reported cases, but not all. Risk of hyperkalemia is increased in pediatric patients with underlying neuromuscular disease (eg, Duchenne muscular dystrophy). Other abnormalities may include elevation in CPK and myoglobinuria. Monitor closely for hyperkalemic-associated arrhythmias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased intracranial pressure: Dilates the cerebral vasculature and may, in certain conditions, increase intracranial pressure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Malignant hyperthermia: May trigger malignant hyperthermia; avoid use in patients susceptible to malignant hyperthermia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory depression: Respiration is depressed as is the normal hyperventilatory response to hypoxia. Hypoxic pulmonary vasoconstriction is depressed which may lead to pulmonary shunt. Hypoxemia-induced increase in ventilation is abolished at low concentrations. Can produce elevated carbon monoxide levels in the presence of a dry carbon dioxide absorbent within the circle breathing system of an anesthetic machine.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F184726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2E1 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2B6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F184679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2E1 Inhibitors (Moderate): May decrease the metabolism of CYP2E1 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2E1 Inhibitors (Strong): May decrease the metabolism of CYP2E1 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOPamine: Inhalational Anesthetics may enhance the arrhythmogenic effect of DOPamine.  Management: Avoid use of dopamine in patients receiving halogenated hydrocarbon anesthetics.  If concomitant treatment cannot be avoided, monitor for arrhythmia.  Dopamine induced ventricular arrhythmia may be reversible with propranolol based on animal data.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     EPHEDrine (Systemic): May enhance the arrhythmogenic effect of Inhalational Anesthetics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     EPINEPHrine (Nasal): Inhalational Anesthetics may enhance the arrhythmogenic effect of EPINEPHrine (Nasal).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     EPINEPHrine (Systemic, Oral Inhalation): Inhalational Anesthetics may enhance the arrhythmogenic effect of EPINEPHrine (Systemic, Oral Inhalation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Formoterol: Inhalational Anesthetics may enhance the arrhythmogenic effect of Formoterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoproterenol: Inhalational Anesthetics may enhance the arrhythmogenic effect of Isoproterenol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May enhance the hypertensive effect of Inhalational Anesthetics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): Inhalational Anesthetics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Norepinephrine: Inhalational Anesthetics may enhance the arrhythmogenic effect of Norepinephrine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F184680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3877948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have demonstrated adverse fetal effects. There are no adequate and well-controlled studies in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F3877950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F184681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, heart rate and rhythm, serum potassium, oxygen saturation, end-tidal CO",
"     <sub>",
"      2",
"     </sub>",
"     and isoflurane concentrations should be monitored prior to and throughout anesthesia",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F184690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aerane (KP);",
"     </li>",
"     <li>",
"      Aerrane (AU, BE, ES, FR, ID, IL, LU, NL, NZ, PH, SG, TW, ZA);",
"     </li>",
"     <li>",
"      Floran (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Florane (PH);",
"     </li>",
"     <li>",
"      Forane (AR, AT, BG, BR, CL, CZ, DE, EE, ES, HK, HN, HR, HU, IE, IL, IT, JP, KP, MY, PE, PH, PK, PL, PY, RU, SG, TH, TR, TW, UY);",
"     </li>",
"     <li>",
"      Forene (BE, CH, DK, FI, FR, LU, NO, SE, VE);",
"     </li>",
"     <li>",
"      Forthane (AU, NZ);",
"     </li>",
"     <li>",
"      Isofluran (FI);",
"     </li>",
"     <li>",
"      Isofluran Pharmacia (FI);",
"     </li>",
"     <li>",
"      Isoflurane (FR, NZ);",
"     </li>",
"     <li>",
"      Isoflurano (CN, EC);",
"     </li>",
"     <li>",
"      Isorane (IN, MX);",
"     </li>",
"     <li>",
"      Sofloran (MX);",
"     </li>",
"     <li>",
"      Terrell Soln (ID)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F184687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 7-10 minutes (pungent odor limits inhalation rate)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Emergence time: Depends on blood concentration when discontinued",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Minimally hepatic (&lt;0.2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily as unmetabolized exhaled gases",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Campagna JA, Miller KW, and Forman SA, &ldquo;Mechanisms of Action of Inhaled Anesthetics,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 348(21):2110-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/63/17397/abstract-text/12761368/pubmed\" id=\"12761368\" target=\"_blank\">",
"        12761368",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      De Hert SG, Turani F, Mathur S, et al, &ldquo;Cardioprotection With Volatile Anesthetics: Mechanisms and Clinical Implications,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2005, 100(6):1584-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/63/17397/abstract-text/15920178 /pubmed\" id=\"15920178 \" target=\"_blank\">",
"        15920178",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ebert TJ and Muzi M, &ldquo;Sympathetic Hyperactivity During Desflurane Anesthesia in Healthy Volunteers. A Comparison With Isoflurane,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1993, 79(3):444-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/63/17397/abstract-text/8363068/pubmed\" id=\"8363068\" target=\"_blank\">",
"        8363068",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eger EI 2nd, &ldquo;Isoflurane: A Review,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1981, 55(5):559-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/63/17397/abstract-text/7027831/pubmed\" id=\"7027831\" target=\"_blank\">",
"        7027831",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fee JP and Thompson GH, &ldquo;Comparative Tolerability Profiles of the Inhaled Anesthetics,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1997, 16(3):157-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/63/17397/abstract-text/9098654/pubmed\" id=\"9098654\" target=\"_blank\">",
"        9098654",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lee MC, Chen CH, Kuo MC, et al, &ldquo;Isoflurane Preconditioning-Induced Cardio-Protection in Patients Undergoing Coronary Artery Bypass Grafting,&rdquo;",
"      <i>",
"       Eur J Anaesthesiol",
"      </i>",
"      , 2006, 23(10):841-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/63/17397/abstract-text/16507192 /pubmed\" id=\"16507192 \" target=\"_blank\">",
"        16507192",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Park KW, &ldquo;Cardiovascular Effects of Inhalational Anesthetics,&rdquo;",
"      <i>",
"       Int Anesthesiol Clin",
"      </i>",
"      , 2002, 40(1):1-14.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stachnik J, &ldquo;Inhaled Anesthetic Agents,&rdquo;",
"      <i>",
"       Am J Health-Syst Pharm",
"      </i>",
"      , 2006, 63(7):623-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/63/17397/abstract-text/16554286/pubmed\" id=\"16554286\" target=\"_blank\">",
"        16554286",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wang L, Traystman RJ, and Murphy SJ, &ldquo;Inhalational Anesthetics as Preconditioning Agents in Ischemic Brain,\"",
"      <i>",
"       Curr Opin Pharmacol",
"      </i>",
"      , 2008, 8(1):104-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/63/17397/abstract-text/17962069 /pubmed\" id=\"17962069 \" target=\"_blank\">",
"        17962069",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yasuda N, Lockhart SH, Eger EI 2nd, et al, &ldquo;Comparison of Kinetics of Sevoflurane and Isoflurane in Humans,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1991, 72(3):316-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/63/17397/abstract-text/1994760/pubmed\" id=\"1994760\" target=\"_blank\">",
"        1994760",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yasuda N, Lockhart SH, Eger EI 2nd, et al, &ldquo;Kinetics of Desflurane, Isoflurane, and Halothane in Humans,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1991, 74(3):489-98.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/63/17397/abstract-text/2001028/pubmed\" id=\"2001028\" target=\"_blank\">",
"        2001028",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8992 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-564C5304BD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_63_17397=[""].join("\n");
var outline_f16_63_17397=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184696\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855043\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184729\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184700\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184701\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16160040\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16160041\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184683\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184673\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184685\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184684\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7871700\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184734\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184727\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184688\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184676\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184726\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184679\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184680\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3877948\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3877950\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184681\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184690\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184687\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8992\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8992|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/54/39780?source=related_link\">",
"      Isoflurane: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_63_17398="Niemann Pick cells";
var content_f16_63_17398=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F75651&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F75651&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Niemann Pick Cells on bone marrow aspirate",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 422px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bone marrow aspirate from a patient with Niemann Pick disease, showing two large macrophages laden with sphingomyelin, giving the cytoplasm a \"foamy\" appearance (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David S Rosenthal, MD and William C Moloney, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_63_17398=[""].join("\n");
var outline_f16_63_17398=null;
var title_f16_63_17399="Brain MRIs ages 20 mo and 9 yrs juvenile Alexander disease";
var content_f16_63_17399=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F74717&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F74717&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Early and late brain MRIs of a patient with autopsy-confirmed juvenile Alexander disease, obtained at ages 20 months and nine years",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 436px; height: 527px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Early (A) and late (B-D) MR  studies of a patient with autopsy-confirmed  juvenile Alexander disease, obtained at  ages 20 months (A) and 9 years (B-D).  The early T2-weighted image (A) shows  extensive cerebral white matter abnormalities with partial sparing of the occipital region. There is a thin periventricular rim of  low signal intensity (arrows, A). The basal  ganglia and thalamus have an increased  signal intensity. The putamen and caudate  nucleus are mildly swollen (A). On follow-up, the extent of the cerebral white matter  abnormalities is more or less the same; the  occipital white matter is still partially  spared (D). The basal nuclei are dark and  atrophic on the T2-weighted images (D). A  thin periventricular rim of low signal intensity is visible (arrows, D). The proton density-weighted image (C) shows enormous  cysts in the frontoparietal white matter, a  large cavum vergae, and enlarged lateral  ventricles. A lesion is seen in the posterior  part of the medulla (B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: van der Knaap MS, Naidu S, Breiter SN, et al. Alexander disease: diagnosis with MR imaging. AJNR Am J Neuroradiol 2001; 22:541. Copyright &copy;2001 American Society of Neuroradiology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_63_17399=[""].join("\n");
var outline_f16_63_17399=null;
var title_f16_63_17400="Mohs surgery";
var content_f16_63_17400=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mohs surgery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/63/17400/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/63/17400/contributors\">",
"     Kishwer Nehal, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/63/17400/contributors\">",
"     Erica Lee, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/63/17400/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/63/17400/contributors\">",
"     Stanley J Miller, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/63/17400/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/63/17400/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/63/17400/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H18481607\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mohs micrographic surgery (MMS) is a specialized surgical technique for removing locally invasive, high risk skin cancers. MMS provides high cure rates with maximal preservation of unaffected tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17400/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. In contrast to standard excision in which only a small portion of the margins are evaluated, in MMS specimens are cut in horizontal sections that allow the evaluation of the entire peripheral and deep margins of the tumor.",
"   </p>",
"   <p>",
"    The most common malignancies treated with MMS are basal cell carcinoma and squamous cell carcinoma. MMS is also used to remove other skin malignancies such as dermatofibrosarcoma protuberans, microcystic adnexal carcinoma, extramammary Paget disease, and lentigo maligna.",
"   </p>",
"   <p>",
"    The MMS technique and its indications will be discussed in this topic. Alternative treatments for skin tumors are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/8/24712?source=see_link\">",
"     \"Treatment of basal cell carcinomas at high risk for recurrence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31209?source=see_link\">",
"     \"Treatment and prognosis of cutaneous squamous cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/46/21226?source=see_link\">",
"     \"Recognition and management of high-risk (aggressive) cutaneous squamous cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13098?source=see_link\">",
"     \"Dermatofibrosarcoma protuberans\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/61/33752?source=see_link\">",
"     \"Microcystic adnexal carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10057?source=see_link\">",
"     \"Lentigo maligna: Clinical manifestations, diagnosis, and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H471540\">",
"    <span class=\"h1\">",
"     HISTORICAL PERSPECTIVE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The original technique, developed by Frederic Mohs in the 1930s, was called &ldquo;fixed-tissue technique&rdquo; or chemosurgery [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17400/abstract/1,2,5\">",
"     1,2,5",
"    </a>",
"    ]. It involved the overnight application of a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/25/32146?source=see_link\">",
"     zinc chloride",
"    </a>",
"    paste to the tumor, which produced tissue necrosis but retained the microscopic architecture. The devitalized, preserved tissue was subsequently excised in a saucer-shaped layer and marked with colored dyes for orientation and correlation on a map. The specimens were then manually flattened, sectioned in the horizontal plane, and stained for histologic examination. In areas of residual tumor, zinc chloride was reapplied overnight and the process repeated until clear margins were achieved.",
"   </p>",
"   <p>",
"    In the following years Mohs surgery evolved from the fixed-tissue to a &ldquo;fresh-tissue technique&rdquo; that used frozen sections of the excised tissue and was initially employed to treat eyelid cancers with a five-year cure rate of 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17400/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. The fresh-tissue technique allows single day excision and repair of the surgical defect in most cases and has become the standard technique for Mohs surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17400/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9314583\">",
"    <span class=\"h1\">",
"     SURGICAL TECHNIQUE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H887631\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mohs micrographic surgery (MMS) is performed under local anesthesia by a dermatologic surgeon formally trained in dermatology and fellowship-trained in MMS, cutaneous oncology, and dermatologic surgery. The tumor is excised at an oblique angle and the beveled specimen is mapped for orientation, sectioned, and processed into frozen horizontal sections for microscopic evaluation of the entire peripheral and deep margins. Residual tumor identified on histologic examination is marked on a pictorial map to guide the removal in subsequent stages until negative margins are achieved. Immediate reconstruction is performed in most cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2779618\">",
"    <span class=\"h2\">",
"     Excision and mapping",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical margins of the biopsy-proven skin cancer are carefully marked with a surgical pen using bright illumination. The skin is prepared with an antiseptic and the site is anesthetized with a local anesthetic (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    1% combined with epinephrine 1:100,000 for vasoconstriction). The tumor can be debulked with a semi-sharp instrument (curette) for a better delineation of the tumor extent. Curetting, however, is not effective for morpheaform basal cell carcinoma or other nonfriable tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17400/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A saucerized or beveled excision of the tumor is performed with a margin of normal-appearing tissue using a scalpel angled at 45 degrees to the skin surface. The margin and depth of tissue initially excised depends upon tumor features and histologic subtype. Narrow margins of one to two mm are taken in sensitive areas, whereas larger margins may be necessary for bulky or recurrent tumors.",
"   </p>",
"   <p>",
"    For superficial tumors the initial excision is shallow, whereas for deeply infiltrating cancers the excision depth may extend to the subcutaneous tissue. Before removing the tissue, reference nicks are placed extending from the tissue onto wound edges (eg, at 12, 3, 6, and 9 o&rsquo;clock positions), to maintain precise anatomic orientation. A diagram (Mohs map) of the surgical defect with anatomic landmarks and location of reference nicks is created (",
"    <a class=\"graphic graphic_picture graphicRef51769 \" href=\"UTD.htm?34/58/35752\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The excised tissue and Mohs map are transferred to the Mohs laboratory for frozen tissue processing with careful attention to preserving tissue orientation. The surgical defect is bandaged and the patient awaits margin examination results [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17400/abstract/7-10\">",
"     7-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Residual tumor identified on histologic examination is marked on a pictorial map to guide the removal in subsequent stages until negative margins are achieved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2779625\">",
"    <span class=\"h2\">",
"     Frozen tissue processing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The excised tissue is processed in an adjacent Mohs laboratory by a specially trained histotechnician under the supervision of the Mohs surgeon [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17400/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The tissue is first subdivided into smaller pieces as necessary to fit onto a cryostat chuck and microscope slide. The pieces are sequentially numbered and cut edges are color coded with two or more dyes for accurate orientation and identification. The subdivision, numbering, and inking pattern are carefully recorded on the Mohs map.",
"   </p>",
"   <p>",
"    To allow the complete examination of the peripheral and deep surgical margins, the angled skin edge is flattened and the tissue is inverted and oriented such that the deep margin and skin edge are aligned in a horizontal plane. Tissue is cut in a cryostat in the horizontal plane into frozen sections five- to seven-microns thick. Sectioned tissue is then fixed and stained with routine hematoxylin and eosin or toluidine blue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2779632\">",
"    <span class=\"h2\">",
"     Histologic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The surgeon evaluates the frozen section margins for residual skin cancer and marks subclinical tumor extensions on the map. A second layer of tissue is excised from the wound at the exact location of the residual tumor with preservation of uninvolved tissue. The process is repeated until a tumor-free plane is achieved (",
"    <a class=\"graphic graphic_picture graphicRef58386 \" href=\"UTD.htm?4/16/4360\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17400/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H471696\">",
"    <span class=\"h2\">",
"     Immunostaining",
"    </span>",
"    &nbsp;&mdash;&nbsp;In high risk skin cancers, immunohistochemical staining may be required for the evaluation of the surgical margins in conjunction with standard staining of frozen sections [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17400/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Rapid immunostains for frozen sections are available, including cytokeratins for squamous cell carcinoma, melan-A (MART-1) for lentigo maligna, and CD34 for dermatofibrosarcoma protuberans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H471703\">",
"    <span class=\"h2\">",
"     Technical pitfalls",
"    </span>",
"    &nbsp;&mdash;&nbsp;The success of MMS can be compromised by pitfalls occurring in any of the many steps of the procedure, including [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17400/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Debulking &mdash; The pre-excision curettage may remove tissue in a nonuniform way, creating jagged margins and floaters.",
"     </li>",
"     <li>",
"      Excising &mdash; A bevel angle &gt;45 degrees may interfere with tissue flattening and require relaxing incisions that can interrupt the margin continuity and confuse orientation.",
"     </li>",
"     <li>",
"      Creating the map &mdash; There is no standardized way to create a map. Hand-drawn pictures are used by most surgeons to map and orient specimens, although this method may not provide a reliable size and shape of the excised area.",
"     </li>",
"     <li>",
"      Subdivision and inking &mdash; Tissue lacerations may occur during sectioning and be mistaken for hash marks; ink may be placed on the wrong margin, or run over the wrong section.",
"     </li>",
"     <li>",
"      Tissue processing &ndash; Pitfalls can also occur during flattening, freezing, sectioning, slide fixation, and staining.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2779639\">",
"    <span class=\"h1\">",
"     RECONSTRUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once Mohs margins are free of cancerous cells, the defect is analyzed to determine the optimal repair technique. Tumor characteristics, location and size of the defect, patient comorbidities, and aesthetic considerations guide the choice of the repair technique. &nbsp;",
"   </p>",
"   <p>",
"    Many Mohs surgical defects can be repaired in a linear manner. Superficial wounds in concave areas such as the medial canthus heal well by second intention. Second intention healing may also be an option for skin cancers at high risk for recurrence in which reconstruction may make tumor surveillance difficult.",
"   </p>",
"   <p>",
"    Larger defects in anatomically sensitive areas require repair with a full thickness skin graft or local flap.",
"   </p>",
"   <p>",
"    For complex cases with defects involving vital structures, collaboration with a reconstructive surgeon specializing in oculoplastics, otorhinolaryngology, or plastic surgery may be necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17400/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1574000248\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10633554\">",
"    <span class=\"h2\">",
"     General indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mohs micrographic surgery (MMS) is primarily indicated for the treatment of locally aggressive tumors at high risk for recurrence. The high risk nature of a cutaneous tumor is determined by tumor characteristics, patient risk factors, and anatomic site (",
"    <a class=\"graphic graphic_table graphicRef54886 \" href=\"UTD.htm?39/52/40779\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Certain anatomic locations offer less resistance to tumor invasion and are associated with deeper and more irregular growth patterns. High risk locations include [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17400/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The embryonic fusion planes &ndash; The medial canthus, paranasal area, alar crease, philtral ridge",
"     </li>",
"     <li>",
"      Skin overlying cartilage such as the pinna of the ear or nasal tip",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recurrent tumors in which the growth pattern may be unpredictable because of scarring and surgical planes from previous surgery are also an indication for MMS.",
"   </p>",
"   <p>",
"    Tumors treated successfully with Mohs surgery have the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tumor amenable to interpretation with frozen sections",
"     </li>",
"     <li>",
"      Tumor growth contiguous for microscopic mapping of subclinical extension",
"     </li>",
"     <li>",
"      Removal of primary tumor with narrow margins adequate",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10634124\">",
"    <span class=\"h2\">",
"     Specific indications",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Basal cell carcinoma",
"      </strong>",
"      &mdash; High risk primary basal cell carcinomas (BCC) and recurrent BCC are the most common tumors treated with MMS. High risk BCCs include tumors &ge;6 mm located in high risk areas (central face, nose, lips, eyelids, eyebrows, periorbital skin, chin, mandible, ears, preauricular and postauricular areas, temples, hands, feet); &ge;10mm in other areas of the face (cheeks, forehead, scalp, and neck); tumors &ge;20 mm on trunk or limbs; or tumors with aggressive pathologic features (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/8/24712?source=see_link&amp;anchor=H12329758#H12329758\">",
"       \"Treatment of basal cell carcinomas at high risk for recurrence\", section on 'Features associated with high risk for recurrence'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Squamous cell carcinoma",
"      </strong>",
"      &mdash; Squamous cell carcinoma (SCC) is the second most common skin cancer treated with MMS. High risk SCCs (eg, tumors &ge;20 mm; involving high-risk areas of the face such as ears and lips; or tumors showing perineural invasion or poor histologic differentiation) are effectively treated with MMS. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31209?source=see_link&amp;anchor=H14#H14\">",
"       \"Treatment and prognosis of cutaneous squamous cell carcinoma\", section on 'High-risk lesions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Dermatofibrosarcoma protuberans",
"      </strong>",
"      &mdash; Dermatofibrosarcoma protuberans (DFSP) is an uncommon, locally aggressive soft tissue sarcoma most often occurring on the trunk and extremities of young to middle aged adults. Because the microscopic extension of DFSP is unpredictable, large defects and numerous tissue sections are often required to achieve negative margins. Reconstruction frequently is delayed by the need for excision of a &ldquo;final&rdquo; margin that is sent for paraffin-embedded permanent sections and immunohistochemistry. Some surgeons perform a modified &ldquo;slow&rdquo; MMS that uses paraffin embedded permanent sections. However, in contrast to the frozen section processing time of one to two hours, paraffin sections require a minimum of 24 to 48 hours. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13098?source=see_link\">",
"       \"Dermatofibrosarcoma protuberans\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Microcystic adnexal carcinoma",
"      </strong>",
"      &mdash; Microcystic adnexal carcinoma is a rare tumor of sweat glands that typically occurs in the head and neck region of older adults. This deeply infiltrative tumor with frequent perineural invasion has a locally aggressive behavior and a high tendency to recur after wide local excision. Recurrence rates with MMS range from 0 to 12 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?16/63/17400/abstract/19,20\">",
"       19,20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Extramammary Paget disease",
"      </strong>",
"      &mdash; Extramammary Paget disease (EMPD) is a slow growing, rare apocrine carcinoma that usually occurs on the genitalia and less commonly the axilla. The recurrence rate is high after wide local excision, despite negative margins. Observational studies indicate that treatment with MMS may be associated with lower recurrence rates [",
"      <a class=\"abstract\" href=\"UTD.htm?16/63/17400/abstract/21-23\">",
"       21-23",
"      </a>",
"      ]. &nbsp;(See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/14/20714?source=see_link\">",
"       \"Vulvar cancer: Staging, treatment, and prognosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Melanoma",
"      </strong>",
"      &mdash; The use of Mohs surgery for treatment of melanoma remains controversial. There are no clinical trials comparing standard excision to MMS. In a consecutive series of 625 patients with head and neck melanoma treated with MMS and followed up for a mean of 58 months, recurrence, metastasis, and disease-specific survival rates were similar or better than historical controls treated with wide excision [",
"      <a class=\"abstract\" href=\"UTD.htm?16/63/17400/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26585?source=see_link&amp;anchor=H8#H8\">",
"       \"Initial surgical management of melanoma of the skin and unusual sites\", section on 'Experimental approaches'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    MMS may be a treatment option for lentigo maligna, a type of melanoma in situ, because of its poorly defined clinical borders, unpredictable subclinical extension, head and neck location requiring tissue conservation, and propensity for recurrence. However, margin assessment with frozen sections can be problematic in lentigo maligna [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17400/abstract/15\">",
"     15",
"    </a>",
"    ]. In a study of 167 patients with melanoma in situ or lentigo maligna, about 5 percent of samples with negative margins on frozen sections were positive on permanent sections [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17400/abstract/25\">",
"     25",
"    </a>",
"    ]. To overcome the limitations of frozen sections, some Mohs surgeons excise and map lentigo maligna with the Mohs technique, but process the tissue with en face paraffin-embedded permanent sections (&ldquo;slow&rdquo; MMS). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10057?source=see_link\">",
"     \"Lentigo maligna: Clinical manifestations, diagnosis, and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Other tumors",
"      </strong>",
"      &mdash; Mohs surgery has been used to treat many other skin tumors, including sebaceous carcinoma, Merkel cell carcinoma, atypical fibroxanthoma, verrucous carcinoma, keratoacanthoma, adenoid cystic carcinoma, angiosarcoma, and leiomyosarcoma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/31/3577?source=see_link\">",
"       \"Staging and treatment of Merkel cell carcinoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/63/4090?source=see_link\">",
"       \"Keratoacanthoma: Epidemiology, risk factors, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Detailed criteria for appropriate use of MMS covering 270 clinical scenarios commonly encountered in clinical practice have been developed by the American Academy of Dermatology in collaboration with the American College of Mohs Surgery, the American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17400/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9483386\">",
"    <span class=\"h1\">",
"     ADVANTAGES AND DISADVANTAGES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9483394\">",
"    <span class=\"h2\">",
"     Advantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Mohs technique offers several advantages over standard surgical excision and pathology processing (",
"    <a class=\"graphic graphic_table graphicRef71211 \" href=\"UTD.htm?27/63/28667\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Better clinicopathologic management of skin cancer. One physician performs the excision of tumor, oversight of tissue processing, and interpretation of frozen sections.",
"     </li>",
"     <li>",
"      Control of the entire surgical margin by using horizontal sections. In contrast, standard excision uses &ldquo;bread loaf&rdquo; vertical sectioning which only permits the evaluation of a small portion of the tumor margins.",
"     </li>",
"     <li>",
"      Maximal preservation of normal tissue in cosmetically and anatomically sensitive areas (around the eyes, nose, lips, and ears).",
"     </li>",
"     <li>",
"      Immediate reconstruction of the defect in most cases.",
"     </li>",
"     <li>",
"      Lower recurrence rates than standard excision for high risk tumors (",
"      <a class=\"graphic graphic_table graphicRef65604 \" href=\"UTD.htm?38/31/39421\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/63/17400/abstract/19,27-29\">",
"       19,27-29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9483401\">",
"    <span class=\"h2\">",
"     Disadvantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;MMS is an extremely labor-intensive procedure. It requires a highly qualified clinician with expertise in the management of high risk skin cancers; an experienced histotechnician with specific training in Mohs frozen tissue processing; a fully certified Mohs laboratory; and well-trained nursing staff.",
"   </p>",
"   <p>",
"    MMS is also a time consuming process that requires patient cooperation and understanding. A typical procedure lasts two to four hours and more complicated cases can take longer. A significant amount of the total time is spent on histologic preparation and analysis. If the patient has serious and labile medical problems or is unwilling to undergo surgery, nonsurgical alternatives such as radiation may be warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9483408\">",
"    <span class=\"h1\">",
"     LIMITATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some instances, complete tumor eradication is not possible with Mohs micrographic surgery (MMS). This may occur when an aggressive skin cancer invades a vital structure and further excision with local anesthesia alone is not feasible in an office setting. In those cases referral to a specialized surgical oncologist is necessary.",
"   </p>",
"   <p>",
"    Skin cancers with perineural invasion, such as squamous cell carcinomas, can recur despite achieving tumor free margins on Mohs frozen sections. A break in tumor continuity can result in a false negative Mohs margin and occurs most frequently in recurrent tumors with scar tissue and fibrosis obscuring residual tumor. False-negative Mohs margins can also occur in tumors with potential for skip areas such as superficial basal cell carcinomas.",
"   </p>",
"   <p>",
"    Frozen section slides may be more difficult to interpret than paraffin-embedded permanent sections [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17400/abstract/30\">",
"     30",
"    </a>",
"    ]. Dense inflammation can be confused with cancer cells or can mask cancerous tissue. Differentiating a basal cell carcinoma from a benign basaloid proliferation or an adnexal structure (eg, trichoepithelioma or tangentially sectioned hair follicle) may be difficult. Pseudocarcinomatous hyperplasia (downward growth of irregular columns of prickle cells into the dermis occurring in wound healing) or tangential sectioning of the epidermis may be mistaken for residual squamous cell carcinoma.",
"   </p>",
"   <p>",
"    In some cases the tumor cannot be reliably identified on frozen sections and accurate diagnosis requires permanent sections and immunohistochemical staining, with delayed wound repair. As an example, residual cells of dermatofibrosarcoma protuberans cannot be clearly differentiated from scattered spindle cells in normal dermis or scar tissue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13098?source=see_link&amp;anchor=H16#H16\">",
"     \"Dermatofibrosarcoma protuberans\", section on 'Mohs micrographic surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Consultation with a dermatopathology colleague face to face or via telepathology can be useful for difficult or rare tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17400/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9483671\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mohs micrographic surgery (MMS) is generally a safe procedure with a low risk of intra- and postoperative complications, which include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bleeding",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hematoma",
"     </li>",
"     <li>",
"      Infection of the wound site",
"     </li>",
"     <li>",
"      Flap or graft necrosis following repair",
"     </li>",
"     <li>",
"      Dehiscence",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In meta-analyses, prospective, and retrospective studies, the overall complication rate ranges from 1.6 to 3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17400/abstract/32-36\">",
"     32-36",
"    </a>",
"    ]. Wound infection has been reported in 0.1 to 2.3 percent of patients undergoing MMS [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17400/abstract/35,37-39\">",
"     35,37-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oral anticoagulants and antiplatelet agents increase the risk of: perioperative complications, as illustrated below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a meta-analysis of patients undergoing cutaneous surgery, severe local complications (hematoma, graft or flap failure, hemorrhage, or dehiscence) occurred in 1.3 percent of patients taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and 5.7 percent of patients taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?16/63/17400/abstract/34\">",
"       34",
"      </a>",
"      ]. The risk of complications among patients taking warfarin was seven times higher than controls (OR 6.7; 95% CI 3.0-14.7).",
"     </li>",
"     <li>",
"      In a prospective study of 1911 patients undergoing MMS or routine cutaneous surgery (including 731 patients who were on anticoagulant therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      ), bleeding complications occurred in less than 1 percent and were associated with the use of warfarin (OR 10; 95% CI 3.5-28.3) or clopidogrel (OR 4.5; 95% CI 1.1-17.3) and with the type of closure (partial, flaps, or graft) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/63/17400/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective study of 743 patients, the risk of intra- or postoperative hemorrhage, hematoma,",
"      <span class=\"nowrap\">",
"       flap/graft",
"      </span>",
"      necrosis, or dehiscence was higher in patients taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      containing regimens than in patients taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      monotherapy (OR 6; 95% CI 1.3-27.6) or no anticoagulants (OR 27.8; 95% CI 1.6-474) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/63/17400/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H473120\">",
"    <span class=\"h1\">",
"     PREOPERATIVE EVALUATION AND MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H473127\">",
"    <span class=\"h2\">",
"     Preoperative consultation",
"    </span>",
"    &nbsp;&mdash;&nbsp;An office-visit with the patient is necessary before Mohs micrographic surgery (MMS) to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Review the patient&rsquo;s medical history and the use of medications, including anticoagulants and nonsteroidal antiinflammatory drugs, or cardiac devices; evaluate the need for antibiotic prophylaxis; assess tobacco and alcohol use.",
"     </li>",
"     <li>",
"      Perform a physical examination of the skin cancer site, surrounding tissue, and draining lymph nodes.",
"     </li>",
"     <li>",
"      Review the diagnosis of skin cancer, treatment options, and advantages and disadvantages of MMS.",
"     </li>",
"     <li>",
"      Discuss the surgery&rsquo;s complications, including infection, bleeding, hematoma or seroma, dehiscence or necrosis following repair, scarring, tumor recurrence, and nerve injury. (See",
"      <a class=\"local\" href=\"#H9483671\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Review the preoperative biopsy before Mohs surgery to confirm the histologic diagnosis of skin cancer.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prior to obtaining the informed consent for Mohs surgery, the patient is asked to verify the site or location of the skin cancer using a mirror if necessary. A photograph of the skin cancer site taken at the time of the biopsy is helpful in accurately identifying the correct location [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17400/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H473134\">",
"    <span class=\"h2\">",
"     Antibiotic prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most MMS procedures do not require antibiotic prophylaxis. However, antibiotic prophylaxis is indicated in the following situations (",
"    <a class=\"graphic graphic_algorithm graphicRef79756 \" href=\"UTD.htm?38/63/39933\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17400/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who are at high risk for surgical site infection, based on the site (lips, ears, nose, groin, or lower extremities) or technique used (skin flaps or grafts).",
"     </li>",
"     <li>",
"      Patients at high risk for infective endocarditis or hematogenous total joint or artificial heart valve infection if surgery involves the oral mucosa [",
"      <a class=\"abstract\" href=\"UTD.htm?16/63/17400/abstract/41,42\">",
"       41,42",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link&amp;anchor=H16#H16\">",
"       \"Antimicrobial prophylaxis for bacterial endocarditis\", section on 'Skin or musculoskeletal tissue'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28198?source=see_link&amp;anchor=H3#H3\">",
"       \"Prevention of prosthetic joint infections\", section on 'Antibiotic prophylaxis prior to invasive procedures'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If the surgical site is infected before the procedure. In this case, cultures should be obtained, aggressive treatment initiated with full-dose antibiotics against",
"      <em>",
"       S. aureus",
"      </em>",
"      and",
"      <em>",
"       S. pyogenes",
"      </em>",
"      , and prophylaxis for infective endocarditis or hematogenous total joint infection provided.",
"     </li>",
"     <li>",
"      If there is an increased risk of methicillin-resistant Staphylococcus aureus (MRSA) infection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4216?source=see_link\">",
"       \"Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H473141\">",
"    <span class=\"h2\">",
"     Anticoagulants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticoagulation is generally safe in patients undergoing MMS if the INR is maintained within the therapeutic range. In contrast, the risk of thromboembolic events increases even after a short period of suspension of anticoagulant therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=see_link&amp;anchor=H10#H10\">",
"     \"Management of anticoagulation before and after elective surgery\", section on 'Dental or excisional cutaneous procedures'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of anticoagulation before and after elective surgery\", section on 'Thrombotic risk if anticoagulation is stopped'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The rate of severe complications among patients undergoing MMS while on oral anticoagulants or antiplatelet agents is low [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17400/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. These complication are not life threatening and are limited to the wound site. Given the balance of risks and benefits, we suggest that anticoagulant therapy be continued for patients undergoing Mohs surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17400/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. &nbsp;(See",
"    <a class=\"local\" href=\"#H9483671\">",
"     'Complications'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18481761\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mohs surgery is a specialized surgical technique for removing high risk skin cancers that provides high cure rates and maximal tissue preservation. (See",
"      <a class=\"local\" href=\"#H18481607\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In Mohs micrographic surgery, tumors are excised under local anesthesia at an oblique angle and mapped on a diagram of the surgical defect. The excised tissue is processed into frozen horizontal sections that allow the histologic evaluation of the entire peripheral and deep margins. Subclinical tumor extensions are precisely marked on the map. A second layer of tissue is subsequently excised at the exact location of the residual tumor with preservation of uninvolved tissue. The process is repeated until negative margins are achieved. Immediate reconstruction is performed in most cases. (See",
"      <a class=\"local\" href=\"#H887631\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mohs surgery is most commonly performed to treat basal cell and squamous cell carcinomas at high risk of recurrence. Mohs surgery is also indicated for other skin malignancies such as dermatofibrosarcoma protuberans, microcystic adnexal carcinoma, and extramammary Paget disease, and for lentigo maligna. (See",
"      <a class=\"local\" href=\"#H1574000248\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/8/24712?source=see_link\">",
"       \"Treatment of basal cell carcinomas at high risk for recurrence\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/46/21226?source=see_link\">",
"       \"Recognition and management of high-risk (aggressive) cutaneous squamous cell carcinoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13098?source=see_link\">",
"       \"Dermatofibrosarcoma protuberans\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10057?source=see_link\">",
"       \"Lentigo maligna: Clinical manifestations, diagnosis, and management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mohs surgery offers several advantages over standard surgical excision, including lower recurrence rates for high risk tumors, maximal tissue preservation in cosmetically and anatomically sensitive areas, and immediate reconstruction in most cases (",
"      <a class=\"graphic graphic_table graphicRef71211 \" href=\"UTD.htm?27/63/28667\">",
"       table 2",
"      </a>",
"      ). However, Mohs surgery is a labor intensive and time consuming process that requires a highly qualified clinician with expertise in the management of high risk skin cancers, a fully certified Mohs laboratory, and specifically trained histotechnician and nursing staff. (See",
"      <a class=\"local\" href=\"#H9483386\">",
"       'Advantages and disadvantages'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mohs surgery is generally a safe procedure with overall complication rates lower than 3 percent. Antibiotic prophylaxis is not needed in most Mohs surgery procedures. However, we suggest antibiotic prophylaxis for patients at high risk of surgical site infection; patients at high risk of infective endocarditis or hematogenous total joint infection, if surgery involves the oral mucosa; or if the surgical site is infected before the procedure. (See",
"      <a class=\"local\" href=\"#H473134\">",
"       'Antibiotic prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anticoagulation is generally safe in patients undergoing MMS if the INR is maintained within the therapeutic range. The reported rates of local complications among patients undergoing Mohs surgery while on anticoagulants range from 1 percent to 3 percent. In contrast, the risk of thromboembolic events increases even after a short period of suspension of anticoagulant therapy. Given the balance of risks and benefits, we suggest that anticoagulant therapy be continued for patients undergoing Mohs surgery. (See",
"      <a class=\"local\" href=\"#H473141\">",
"       'Anticoagulants'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=see_link&amp;anchor=H10#H10\">",
"       \"Management of anticoagulation before and after elective surgery\", section on 'Dental or excisional cutaneous procedures'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=see_link&amp;anchor=H3#H3\">",
"       \"Management of anticoagulation before and after elective surgery\", section on 'Thrombotic risk if anticoagulation is stopped'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18481768\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors would like to thank Indira Singh for photography and January Brown for editing.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17400/abstract/1\">",
"      Hanke CW. Frederic Mohs Tribute. History of Mohs micrographic surgery. J Drugs Dermatol 2002; 1:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17400/abstract/2\">",
"      Brodland DG, Amonette R, Hanke CW, Robins P. The history and evolution of Mohs micrographic surgery. Dermatol Surg 2000; 26:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17400/abstract/3\">",
"      Tromovitch TA, Stegeman SJ. Microscopically controlled excision of skin tumors. Arch Dermatol 1974; 110:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17400/abstract/4\">",
"      Mohs FE. Chemosurgery for skin cancer: fixed tissue and fresh tissue techniques. Arch Dermatol 1976; 112:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17400/abstract/5\">",
"      Mohs, FE. Chemosurgery, a microscopically controlled method of cancer excision. Arch Surg 1941; 42:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17400/abstract/6\">",
"      Lee DA, Ratner D. Economic impact of preoperative curettage before Mohs micrographic surgery for basal cell carcinoma. Dermatol Surg 2006; 32:916.",
"     </a>",
"    </li>",
"    <li>",
"     Gross KG, Steinman HK. Lab Pearls: Making Great Slides. In: Mohs surgery and histopathology: beyond the fundamentals, Cambridge University Press, 2009. p.37.",
"    </li>",
"    <li>",
"     Gross KG, Steinman HK. How to Excise Tissue for Optimal Sectioning. In: Mohs surgery and histopathology: beyond the fundamentals, Cambridge University Press, 2009. p.5.",
"    </li>",
"    <li>",
"     Gross KG, Steinman HK. Lab Pearls: Staining, Inking and Coverslipping. In: Mohs surgery and histopathology: beyond the fundamentals, Cambridge University Press, 2009. p.57.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17400/abstract/10\">",
"      Cumberland L, Dana A, Liegeois N. Mohs micrographic surgery for the management of nonmelanoma skin cancers. Facial Plast Surg Clin North Am 2009; 17:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17400/abstract/11\">",
"      Thornton SL, Beck B. Setting up the Mohs surgery laboratory. Dermatol Clin 2011; 29:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17400/abstract/12\">",
"      El Tal AK, Abrou AE, Stiff MA, Mehregan DA. Immunostaining in Mohs micrographic surgery: a review. Dermatol Surg 2010; 36:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17400/abstract/13\">",
"      Stranahan DR, Cherpelis BS, Fenske NA, Glass LF. Advances in immunostains used in Mohs surgery. J Drugs Dermatol 2010; 9:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17400/abstract/14\">",
"      Miller CJ, Sobanko JF, Zhu X, et al. Special stains in Mohs surgery. Dermatol Clin 2011; 29:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17400/abstract/15\">",
"      Bouzari N, Olbricht S. Histologic pitfalls in the Mohs technique. Dermatol Clin 2011; 29:261.",
"     </a>",
"    </li>",
"    <li>",
"     Brodland DG, Pharis D. Flaps. In: Dermatology, Bolognia JL, Jorizzo JL, Rapini RP (Eds), Mosby, 2003. p.2287.",
"    </li>",
"    <li>",
"     Ratner D. Grafts. In: Dermatology, Bolognia JL, Jorizzo JL, Rapini RP (Eds), Mosby, 2003. p.2305.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17400/abstract/18\">",
"      Shriner DL, McCoy DK, Goldberg DJ, Wagner RF Jr. Mohs micrographic surgery. J Am Acad Dermatol 1998; 39:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17400/abstract/19\">",
"      Leibovitch I, Huilgol SC, Selva D, et al. Microcystic adnexal carcinoma: treatment with Mohs micrographic surgery. J Am Acad Dermatol 2005; 52:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17400/abstract/20\">",
"      Diamantis SA, Marks VJ. Mohs micrographic surgery in the treatment of microcystic adnexal carcinoma. Dermatol Clin 2011; 29:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17400/abstract/21\">",
"      Hendi A, Brodland DG, Zitelli JA. Extramammary Paget's disease: surgical treatment with Mohs micrographic surgery. J Am Acad Dermatol 2004; 51:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17400/abstract/22\">",
"      Lee KY, Roh MR, Chung WG, Chung KY. Comparison of Mohs micrographic surgery and wide excision for extramammary Paget's Disease: Korean experience. Dermatol Surg 2009; 35:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17400/abstract/23\">",
"      O'Connor WJ, Lim KK, Zalla MJ, et al. Comparison of mohs micrographic surgery and wide excision for extramammary Paget's disease. Dermatol Surg 2003; 29:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17400/abstract/24\">",
"      Bricca GM, Brodland DG, Ren D, Zitelli JA. Cutaneous head and neck melanoma treated with Mohs micrographic surgery. J Am Acad Dermatol 2005; 52:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17400/abstract/25\">",
"      Bene NI, Healy C, Coldiron BM. Mohs micrographic surgery is accurate 95.1% of the time for melanoma in situ: a prospective study of 167 cases. Dermatol Surg 2008; 34:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17400/abstract/26\">",
"      Ad Hoc Task Force, Connolly SM, Baker DR, et al. AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery. J Am Acad Dermatol 2012; 67:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17400/abstract/27\">",
"      Leibovitch I, Huilgol SC, Selva D, et al. Cutaneous squamous cell carcinoma treated with Mohs micrographic surgery in Australia I. Experience over 10 years. J Am Acad Dermatol 2005; 53:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17400/abstract/28\">",
"      Leibovitch I, Huilgol SC, Selva D, et al. Basal cell carcinoma treated with Mohs surgery in Australia II. Outcome at 5-year follow-up. J Am Acad Dermatol 2005; 53:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17400/abstract/29\">",
"      Mosterd K, Krekels GA, Nieman FH, et al. Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up. Lancet Oncol 2008; 9:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17400/abstract/30\">",
"      Hitchcock MG, Leshin B, White WL. Pitfalls in frozen section interpretation in Mohs micrographic surgery. Adv Dermatol 1997; 13:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17400/abstract/31\">",
"      Sukal SA, Busam KJ, Nehal KS. Clinical application of dynamic telepathology in Mohs surgery. Dermatol Surg 2005; 31:1700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17400/abstract/32\">",
"      Bordeaux JS, Martires KJ, Goldberg D, et al. Prospective evaluation of dermatologic surgery complications including patients on multiple antiplatelet and anticoagulant medications. J Am Acad Dermatol 2011; 65:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17400/abstract/33\">",
"      Cook-Norris RH, Michaels JD, Weaver AL, et al. Complications of cutaneous surgery in patients taking clopidogrel-containing anticoagulation. J Am Acad Dermatol 2011; 65:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17400/abstract/34\">",
"      Lewis KG, Dufresne RG Jr. A meta-analysis of complications attributed to anticoagulation among patients following cutaneous surgery. Dermatol Surg 2008; 34:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17400/abstract/35\">",
"      Cook JL, Perone JB. A prospective evaluation of the incidence of complications associated with Mohs micrographic surgery. Arch Dermatol 2003; 139:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17400/abstract/36\">",
"      Merritt BG, Lee NY, Brodland DG, et al. The safety of Mohs surgery: a prospective multicenter cohort study. J Am Acad Dermatol 2012; 67:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17400/abstract/37\">",
"      Maragh SL, Brown MD. Prospective evaluation of surgical site infection rate among patients with Mohs micrographic surgery without the use of prophylactic antibiotics. J Am Acad Dermatol 2008; 59:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17400/abstract/38\">",
"      Futoryan T, Grande D. Postoperative wound infection rates in dermatologic surgery. Dermatol Surg 1995; 21:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17400/abstract/39\">",
"      Rhinehart MB, Murphy MM, Farley MF, Albertini JG. Sterile versus nonsterile gloves during Mohs micrographic surgery: infection rate is not affected. Dermatol Surg 2006; 32:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17400/abstract/40\">",
"      Wright TI, Baddour LM, Berbari EF, et al. Antibiotic prophylaxis in dermatologic surgery: advisory statement 2008. J Am Acad Dermatol 2008; 59:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17400/abstract/41\">",
"      Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007; 116:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17400/abstract/42\">",
"      American Dental Association, American Academy of Orthopedic Surgeons. Antibiotic prophylaxis for dental patients with total joint replacements. J Am Dent Assoc 2003; 134:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17400/abstract/43\">",
"      Douketis JD, Berger PB, Dunn AS, et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:299S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17400/abstract/44\">",
"      Korte W, Cattaneo M, Chassot PG, et al. Peri-operative management of antiplatelet therapy in patients with coronary artery disease: joint position paper by members of the working group on Perioperative Haemostasis of the Society on Thrombosis and Haemostasis Research (GTH), the working group on Perioperative Coagulation of the Austrian Society for Anesthesiology, Resuscitation and Intensive Care (&Ouml;GARI) and the Working Group Thrombosis of the European Society for Cardiology (ESC). Thromb Haemost 2011; 105:743.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13708 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-27EA24A548-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_63_17400=[""].join("\n");
var outline_f16_63_17400=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18481761\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18481607\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H471540\">",
"      HISTORICAL PERSPECTIVE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9314583\">",
"      SURGICAL TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H887631\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2779618\">",
"      Excision and mapping",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2779625\">",
"      Frozen tissue processing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2779632\">",
"      Histologic examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H471696\">",
"      Immunostaining",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H471703\">",
"      Technical pitfalls",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2779639\">",
"      RECONSTRUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1574000248\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10633554\">",
"      General indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10634124\">",
"      Specific indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9483386\">",
"      ADVANTAGES AND DISADVANTAGES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9483394\">",
"      Advantages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9483401\">",
"      Disadvantages",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9483408\">",
"      LIMITATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9483671\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H473120\">",
"      PREOPERATIVE EVALUATION AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H473127\">",
"      Preoperative consultation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H473134\">",
"      Antibiotic prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H473141\">",
"      Anticoagulants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18481761\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18481768\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/13708\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13708|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?38/63/39933\" title=\"algorithm 1\">",
"      Antibiotic prophylaxis in dermatologic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13708|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/58/35752\" title=\"picture 1\">",
"      Mohs surgery 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/16/4360\" title=\"picture 2\">",
"      Mohs surgery 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13708|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/52/40779\" title=\"table 1\">",
"      Criteria for MMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/63/28667\" title=\"table 2\">",
"      Mohs versus standard excision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/31/39421\" title=\"table 3\">",
"      Recurrence rates after MMS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13098?source=related_link\">",
"      Dermatofibrosarcoma protuberans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26585?source=related_link\">",
"      Initial surgical management of melanoma of the skin and unusual sites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/63/4090?source=related_link\">",
"      Keratoacanthoma: Epidemiology, risk factors, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10057?source=related_link\">",
"      Lentigo maligna: Clinical manifestations, diagnosis, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=related_link\">",
"      Management of anticoagulation before and after elective surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/61/33752?source=related_link\">",
"      Microcystic adnexal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28198?source=related_link\">",
"      Prevention of prosthetic joint infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/46/21226?source=related_link\">",
"      Recognition and management of high-risk (aggressive) cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/31/3577?source=related_link\">",
"      Staging and treatment of Merkel cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31209?source=related_link\">",
"      Treatment and prognosis of cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/8/24712?source=related_link\">",
"      Treatment of basal cell carcinomas at high risk for recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4216?source=related_link\">",
"      Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/14/20714?source=related_link\">",
"      Vulvar cancer: Staging, treatment, and prognosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_63_17401="Methylprednisolone: Pediatric drug information";
var content_f16_63_17401=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Methylprednisolone: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"    see \"Methylprednisolone: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?14/5/14422?source=see_link\">",
"    see \"Methylprednisolone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F15254327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Fungal Meningitis Outbreak Associated with Contaminated Injectables",
"     </span>",
"     <span class=\"collapsible-date\">",
"      October 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For information regarding the recent meningitis outbreak from products compounded by the New England Compounding Center (NECC), including treatment recommendations, please refer to the following websites:",
"      </p>",
"      <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">",
"       <a href=\"file://www.cdc.gov/hai/outbreaks/meningitis.html\" target=\"_blank\">",
"        file://www.cdc.gov/hai/outbreaks/meningitis.html",
"       </a>",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"       <a href=\"file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm285497.htm\" target=\"_blank\">",
"        file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm285497.htm",
"       </a>",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"       <a href=\"file://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm323947.htm?source=govdelivery\" target=\"_blank\">",
"        file://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm323947.htm?source=govdelivery",
"       </a>",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F195382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      A-Methapred&reg;;",
"     </li>",
"     <li>",
"      Depo-Medrol&reg;;",
"     </li>",
"     <li>",
"      Medrol&reg;;",
"     </li>",
"     <li>",
"      Medrol&reg; Dosepak&trade;;",
"     </li>",
"     <li>",
"      Solu-MEDROL&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F195383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Depo-Medrol&reg;;",
"     </li>",
"     <li>",
"      Medrol&reg;;",
"     </li>",
"     <li>",
"      Methylprednisolone Acetate;",
"     </li>",
"     <li>",
"      Solu-Medrol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1053999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Adrenal Corticosteroid",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-inflammatory Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiasthmatic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Corticosteroid, Systemic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Glucocorticoid",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1053992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"      see \"Methylprednisolone: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Adjust dose depending upon condition being treated and response of patient. The lowest possible dose should be used to control the condition; when dose reduction is possible, the dose should be reduced gradually. In life-threatening situations, parenteral doses larger than the oral dose may be needed.",
"     <b>",
"      Only sodium succinate salt may be given I.V.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Asthma, exacerbation:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Acute, short-course &ldquo;burst&rdquo;",
"     </i>",
"     (NAEPP, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Infants and Children &lt;12 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Oral: 1-2 mg/kg/day in divided doses once or twice daily for 3-10 days; maximum daily dose: 60 mg/",
"     <b>",
"      day",
"     </b>",
"     ;",
"     <b>",
"      Note:",
"     </b>",
"     Burst should be continued until symptoms resolve or patient achieves peak expiratory flow 80% of personal best; usually requires 3-10 days of treatment (~5 days on average); longer treatment may be required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     I.M.",
"     <b>",
"      (acetate)",
"     </b>",
"     :",
"     <b>",
"      Note:",
"     </b>",
"     This may be given in place of short-course &ldquo;burst&rdquo; of oral steroids in patients who are vomiting or if compliance is a problem.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     Children &le;4 years: 7.5 mg/kg as a one-time dose; maximum dose: 240 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     Children 5-11 years: 240 mg as a one-time dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Children &ge;12 years and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Oral: 40-60 mg/day in divided doses once or twice daily for 3-10 days;",
"     <b>",
"      Note:",
"     </b>",
"     Burst should be continued until symptoms resolve and peak expiratory flow is at least 80% of personal best; usually requires 3-10 days of treatment (~5 days on average); longer treatment may be required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     I.M.",
"     <b>",
"      (acetate)",
"     </b>",
"     : 240 mg as a one-time dose;",
"     <b>",
"      Note:",
"     </b>",
"     This may be given in place of short-course &ldquo;burst&rdquo; of oral steroids in patients who are vomiting or if compliance is a problem",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Hospital/emergency medical care doses:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Infants and Children &lt;12 years: Oral, I.V.: 1-2 mg/kg/day in 2 divided doses; maximum daily dose: 60 mg/",
"     <b>",
"      day",
"     </b>",
"     ; continue until peak expiratory flow is 70% of predicted or personal best",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Children &ge;12 years and Adolescents: Oral, I.V.: 40-80 mg/day in divided doses once or twice daily until peak expiratory flow is 70% of predicted or personal best",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Status asthmaticus",
"     </i>",
"     (previous NAEPP guidelines; still used by some clinicians): Children: I.V.: Loading dose: 2 mg/kg/dose, then 0.5-1   	mg/kg/dose every 6 hours;",
"     <b>",
"      Note:",
"     </b>",
"     See NAEPP 2007 guidelines for asthma exacerbations (emergency medical care or hospital doses) listed above",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Asthma, long-term treatment (maintenance)",
"     </b>",
"     (NAEPP, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Infants and Children &lt;12 years: Oral: 0.25-2 mg/kg/day  once daily in the morning or every other day as needed for asthma control; maximum daily dose: 60 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &ge;12 years and Adolescents: Oral: 7.5-60 mg daily once daily in the morning or every other day as needed for asthma control",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Anti-inflammatory or immunosuppressive:",
"     </b>",
"     Oral, I.M. (acetate or succinate), I.V. (succinate): 0.5-1.7 mg/kg/day or 5-25 mg/",
"     <b>",
"      m",
"     </b>",
"     <sup>",
"      2",
"     </sup>",
"     /day in divided doses every 6-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &ldquo;Pulse&rdquo; therapy: I.V. (succinate): 15-30 mg/kg/dose once daily for 3 days; maximum dose: 1000 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Lupus nephritis:",
"     </b>",
"     Children and Adolescents: I.V. (succinate): High-dose \"pulse\" therapy: 30 mg/kg/dose or 600-1000 mg/",
"     <b>",
"      m",
"     </b>",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily for 3 days; maximum dose: 1000 mg (Adams, 2006; Marks, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Spinal cord injury, acute:",
"     </b>",
"     Children and Adolescents: I.V. (succinate): 30 mg/kg over 15 minutes followed in 45 minutes by a continuous infusion of 5.4 mg/kg/hour for 23 hours;",
"     <b>",
"      Note:",
"     </b>",
"     Due to insufficient evidence of clinical efficacy (ie, preserving or improving spinal cord function), the routine use of methylprednisolone in the treatment of acute spinal cord injury is no longer recommended. If used in this setting, methylprednisolone should not be initiated &gt;8 hours after the injury; not effective in penetrating trauma (eg, gunshot) (Consortium for Spinal Cord Medicine, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      <i>",
"       Pneumocystis",
"      </i>",
"      pneumonia; moderate or severe infection:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Initiate therapy within 72 hours of diagnosis, if possible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Infants and Children: I.V. (succinate): 1 mg/kg/dose every 6 hours on days 1-7, then 1 mg/kg/dose twice daily on days 8-9, then 0.5 mg/kg/dose twice daily on days 10 and 11, and 1 mg/kg/dose once daily on days 12-16 (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adolescents: I.V. (succinate): 30 mg twice daily on days 1-5, then 30 mg once daily on days 6-10, then 15 mg once daily on days 11-21 (CDC, 2009a)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Graft-versus-host disease, acute (GVHD):",
"     </b>",
"     I.V. (succinate): 1-2 mg/kg/dose once daily; if using low dose (1 mg/kg) and no improvement after 3 days, increase dose to 2 mg/kg. Continue therapy for 5-7 days; if improvement observed, may taper by 10% of starting dose every 4 days; if no improvement, then considered steroid-refractory GVHD and additional agents should be considered (Carpenter, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Allergic conditions:",
"     </b>",
"     Oral: Tapered-dosage schedule (eg, dose-pack containing 21 x 4 mg tablets):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Day 1: 24 mg on day 1 administered as 8 mg (2 tablets) before breakfast, 4 mg (1 tablet) after lunch, 4 mg (1 tablet) after supper, and 8 mg (2 tablets) at bedtime",
"     <b>",
"      OR",
"     </b>",
"     24 mg (6 tablets) as a single dose or divided into 2 or 3 doses upon initiation (regardless of time of day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Day 2: 20 mg on day 2 administered as 4 mg (1 tablet) before breakfast, 4 mg (1 tablet) after lunch, 4 mg (1 tablet) after supper, and 8 mg (2 tablets) at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Day 3: 16 mg on day 3 administered as 4 mg (1 tablet) before breakfast, 4 mg (1 tablet) after lunch, 4 mg (1 tablet) after supper, and 4 mg (1 tablet) at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Day 4: 12 mg on day 4 administered as 4 mg (1 tablet) before breakfast, 4 mg (1 tablet) after lunch, and 4 mg (1 tablet) at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Day 5: 8 mg on day 5 administered as 4 mg (1 tablet) before breakfast and 4 mg (1 tablet) at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Day 6: 4 mg on day 6 administered as 4 mg (1 tablet) before breakfast",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Anti-inflammatory or immunosuppressive:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Oral: 2-60 mg/day in 1-4 divided doses to start, followed by gradual reduction in dosage to the lowest possible level consistent with maintaining an adequate clinical response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.M. (sodium succinate): 10-80 mg/day once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.M. (acetate): 10-80 mg every 1-2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.V. (sodium succinate): 10-40 mg over a period of several minutes and repeated I.V. or I.M. at intervals depending on clinical response; when high dosages are needed, give 30 mg/kg over a period &ge;30 minutes and may be repeated every 4-6 hours for 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Arthritis:",
"     </b>",
"     Intra-articular (acetate): Administer every 1-5 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Large joints (eg, knee, ankle): 20-80 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Medium joints (eg, elbow, wrist): 10-40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Small joints: 4-10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Asthma exacerbations, including status asthmaticus (emergency medical care or hospital doses):",
"     </b>",
"     Oral, I.V.: 40-80 mg/day in 1-2 divided doses until peak expiratory flow is 70% of predicted or personal best (NIH Asthma Guidelines, NAEPP, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Asthma, severe persistent, long-term control:",
"     </b>",
"     Oral: 7.5-60 mg/day (or on alternate days) (NIH Asthma Guidelines, NAEPP, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Dermatitis, acute severe:",
"     </b>",
"     I.M. (acetate): 80-120 mg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Dermatitis, chronic:",
"     </b>",
"     I.M. (acetate): 40-120 mg every 5-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Dermatologic conditions (eg, keloids, lichen planus):",
"     </b>",
"     Intralesional (acetate): 20-60 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Dermatomyositis/polymyositis:",
"     </b>",
"     I.V. (sodium succinate): 1000 mg/day for 3-5 days for severe muscle weakness, followed by conversion to oral prednisone (Drake, 1996)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Lupus nephritis:",
"     </b>",
"     High-dose &ldquo;pulse&rdquo; therapy: I.V. (sodium succinate): 500-1000 mg/day for 3 days (Ponticelli, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      <i>",
"       Pneumocystis",
"      </i>",
"      pneumonia in AIDS patients:",
"     </b>",
"     I.V.: 30 mg twice daily for 5 days, then 30 mg once daily for 5 days, then 15 mg once daily for 11 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Slightly dialyzable (5% to 20%); administer dose posthemodialysis",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F195358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as sodium succinate [strength expressed as base]: 40 mg, 125 mg, 500 mg, 1 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     A-Methapred&reg;: 40 mg [contains benzyl alcohol (in diluent), lactose 25 mg/vial]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     A-Methapred&reg;: 40 mg [contains lactose 25 mg/vial]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     A-Methapred&reg;: 125 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     A-Methapred&reg;: 125 mg [contains benzyl alcohol (in diluent)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Solu-MEDROL&reg;: 500 mg, 1 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Solu-MEDROL&reg;: 2 g [contains benzyl alcohol (in diluent)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as sodium succinate [strength expressed as base, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Solu-MEDROL&reg;: 40 mg [contains lactose 25 mg/vial; supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Solu-MEDROL&reg;: 125 mg, 500 mg, 1 g [supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, suspension, as acetate: 40 mg/mL (1 mL, 5 mL, 10 mL); 80 mg/mL (1 mL, 5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Depo-Medrol&reg;: 20 mg/mL (5 mL) [contains benzyl alcohol, polysorbate 80]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Depo-Medrol&reg;: 40 mg/mL (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Depo-Medrol&reg;: 40 mg/mL (5 mL, 10 mL); 80 mg/mL (5 mL) [contains benzyl alcohol, polysorbate 80]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, suspension, as acetate [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Depo-Medrol&reg;: 80 mg/mL (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 4 mg, 8 mg, 16 mg, 32 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Medrol&reg;: 2 mg, 4 mg, 8 mg, 16 mg, 32 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral [dose-pack]: 4 mg [21s]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Medrol&reg; Dosepak&trade;: 4 mg [scored; 21s]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F195342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes preservative free injection",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1054003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer after meals or with food or milk; do not administer with grapefruit juice; if prescribed once daily, administer dose in the early morning to mimic the normal diurnal variation of endogenous cortisol",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.:",
"     <b>",
"      Acetate, Succinate:",
"     </b>",
"     Avoid injection into the deltoid muscle due to a high incidence of subcutaneous atrophy. Do not inject into areas that have evidence of acute local infection. Discard contents of single-dose vial after use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.:",
"     <b>",
"      Succinate:",
"     </b>",
"     Rate dependent upon dose; typically intermittent infusion is administered over 15-60 minutes. Do not administer moderate or high dose I.V. push; severe adverse effects, including hypotension, cardiac arrhythmia, and sudden death, have been reported in patients receiving high-dose methylprednisolone I.V. push over &lt;20 minutes.",
"     <b>",
"      Do not give acetate form I.V.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Low  dose (eg, &le;1.8 mg/kg or &le;125 mg/dose): I.V. push over 3-15 minutes; maximum concentration: 125 mg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Moderate dose (eg, &ge;2 mg/kg or 250 mg/dose): Administer over 15-30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     High dose (eg, &ge;15 mg/kg or &ge;500 mg/dose): Administer over 30-60 minutes; doses &ge;1000 mg: Administer over 60 minutes.",
"     <b>",
"      Note:",
"     </b>",
"     In some of the adult spinal cord injury trials, bolus doses (30 mg/kg) have been administered over 15 minutes.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F195435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Stable",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, LR, NS;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, alprostadil, amifostine, amiodarone, amphotericin B cholesteryl sulfate complex, anidulafungin, aztreonam, bivalirudin, cefepime, ceftazidime, cisplatin, cladribine, cyclophosphamide, cytarabine, dexmedetomidine, dopamine, doripenem, doxorubicin, doxorubicin liposome, enalaprilat, famotidine, fludarabine, granisetron, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), inamrinone, linezolid, melphalan, meperidine, methotrexate, metronidazole, milrinone, morphine, nicardipine, oxaliplatin, pemetrexed, piperacillin/tazobactam, prochlorperazine, remifentanil, sodium bicarbonate, tacrolimus, teniposide, theophylline, thiotepa, topotecan.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Allopurinol, amsacrine, caspofungin, ciprofloxacin, docetaxel, etoposide phosphate, fenoldopam, filgrastim, gemcitabine, ondansetron, paclitaxel, palonosetron, propofol, sargramostim, tigecycline, vinorelbine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Aminophylline, cisatracurium, diltiazem, fosaprepitant, heparin with hydrocortisone sodium succinate, midazolam, pantoprazole, potassium chloride, telavancin, vitamin B complex with C.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Granisetron, iohexol, iopamidol, iothalamate meglumine 60%, ioxaglate meglumine 39.3% and ioxaglate sodium 19.6%, metoclopramide.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Doxapram, pantoprazole.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Midazolam.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F9522886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Tablets: Store 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Methylprednisolone sodium succinate: Store intact vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from light. Store reconstituted solutions at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); use within 48 hours. Reconstitute with accompanying diluent or bacteriostatic water for injection with benzyl alcohol. May further dilute in D",
"     <sub>",
"      5",
"     </sub>",
"     W,  NS or D",
"     <sub>",
"      5",
"     </sub>",
"     NS. Stability of parenteral admixture at room temperature (25&deg;C) and at refrigeration temperature (4&deg;C) is 48 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Methylprednisolone acetate: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Do",
"     <b>",
"      not",
"     </b>",
"     dilute or mix with other solutions.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1054002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Systemic: Tablets, parenteral (I.V., I.M.): Anti-inflammatory or immunosuppressant agent in the treatment of a variety of diseases including those of hematologic, allergic, inflammatory, neoplastic, and autoimmune origin (FDA approved in ages &gt;1 month and adults); has also been used for acute spinal cord injury,",
"     <i>",
"      Pneumocystis",
"     </i>",
"     pneumonia,  and prevention and treatment of graft-versus-host disease following allogeneic bone marrow transplantation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Local: Depot formulations (Depo-Medrol&reg;): [FDA approved in pediatric patients (age not specified) and adults]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Intra-articular (or soft tissue): Acute gouty arthritis, acute/subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Intralesional (injectable suspension): Alopecia areata; discoid lupus erythematosus; infiltrated, inflammatory lesions associated with granuloma annulare, lichen planus, neurodermatitis, and psoriatic plaques; keloids; necrobiosis lipoidica diabeticorum; possibly helpful in cystic tumors of an aponeurosis or tendon (ganglia)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F195438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       MethylPREDNISolone may be confused with medroxyPROGESTERone, methotrexate, methylTESTOSTERone, predniSONE",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Depo-Medrol&reg; may be confused with Solu-Medrol&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Medrol&reg; may be confused with Mebaral&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Solu-MEDROL&reg; may be confused with salmeterol, Solu-CORTEF&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Medrol [U.S., Canada, and multiple international markets] may be confused with Medral brand name for omeprazole [Mexico]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F195434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmias, bradycardia, cardiac arrest, cardiomegaly, circulatory collapse, congestive heart failure, edema, fat embolism, hypertension, hypertrophic cardiomyopathy in premature infants, myocardial rupture (post MI), syncope, tachycardia, thromboembolism, vasculitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Delirium, depression, emotional instability, euphoria, hallucinations, headache, intracranial pressure increased,  insomnia, malaise, mood swings, nervousness, neuritis, personality changes, psychic disorders, pseudotumor cerebri (usually following discontinuation), seizure, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Acne, allergic dermatitis, alopecia, dry scaly skin, ecchymoses, edema, erythema, hirsutism, hyper-/hypopigmentation, hypertrichosis, impaired wound healing, petechiae, rash, skin atrophy, sterile abscess, skin test reaction impaired, striae, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Adrenal suppression, amenorrhea, carbohydrate intolerance increased, Cushing's syndrome, diabetes mellitus, fluid retention, glucose intolerance, growth suppression (children),  hyperglycemia, hyperlipidemia, hypokalemia, hypokalemic alkalosis, menstrual irregularities, negative nitrogen balance, pituitary-adrenal axis suppression, protein catabolism, sodium and water retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal distention, appetite increased, bowel/bladder dysfunction (after intrathecal administration), gastrointestinal hemorrhage, gastrointestinal perforation, nausea, pancreatitis, peptic ulcer, perforation of the small and large intestine, ulcerative esophagitis, vomiting, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Leukocytosis (transient)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatomegaly, transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Postinjection flare (intra-articular use), thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, arthropathy, aseptic necrosis (femoral and humoral heads), fractures, muscle mass loss, muscle weakness, myopathy (particularly in conjunction with neuromuscular disease or neuromuscular-blocking agents), neuropathy, osteoporosis, parasthesia, tendon rupture, vertebral compression fractures, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Cataracts, exophthalmoses, glaucoma, intraocular pressure increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Glycosuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pulmonary edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Abnormal fat disposition, anaphylactoid reaction, anaphylaxis, angioedema, avascular necrosis, diaphoresis, hiccups, hypersensitivity reactions, infections, secondary malignancy",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1054006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to methylprednisolone or any component; systemic fungal infections (except intra-articular injection in localized joint conditions); intrathecal administration; for immunosuppressive doses: Administration of live or live, attenuated vaccines",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Additional patient-type contraindications:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Premature neonates: Formulations containing benzyl alcohol preservative",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Idiopathic thrombocytopenia purpura:  I.M. administration",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1053991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid using higher than recommended doses; suppression of HPA function, suppression of linear growth (ie, reduction of growth velocity), reduced bone mineral density, hypercorticism (Cushing's syndrome), hyperglycemia, or glucosuria may occur; titrate to lowest effective dose. Reduction in growth velocity may occur when corticosteroids are administered to pediatric patients by any route (monitor growth). Use with extreme caution in patients with respiratory tuberculosis or untreated systemic infections. Use with caution in patients with hypertension, heart failure, or renal impairment; long-term use has been associated with fluid retention and hypertension. Use with caution in patients with GI diseases (diverticulitis, peptic ulcer, ulcerative colitis) due to risk of GI bleeding and perforation. Use with caution in patients with myasthenia gravis; exacerbation of symptoms has occurred, especially during initial treatment with corticosteroids. Use with caution in patients with hepatic impairment, including cirrhosis; enhanced pharmacologic effect due to decreased metabolism and long-term use has been associated with fluid retention. Use with caution following acute MI; corticosteroids have been associated with myocardial rupture; hypertrophic cardiomyopathy has been reported in premature neonates.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution in patients with diabetes; corticosteroids may alter glucose regulation, leading to hyperglycemia. Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use; consider routine eye exams in chronic users. Use with caution in patients with a history of seizure disorder; seizures have been reported with adrenal crisis. Use with caution in patients with thyroid dysfunction; changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid patients. Prolonged treatment with corticosteroids has been associated with the development of Kaposi's sarcoma (case reports); if noted, discontinuation of therapy should be considered. Use with caution in patients with thromboembolic tendencies or thrombophlebitis. Avoid injection into an infected site. Response to killed or inactivated vaccines cannot be predicted in patients receiving immunosuppressive doses of corticosteroids.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Systemic use is not recommended in the treatment of optic neuritis; an increased risk of new episodes may occur.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1053990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypothalamic-pituitary-adrenal (HPA) suppression may occur, particularly in younger children or in patients receiving high doses for prolonged periods; acute adrenal insufficiency (adrenal crisis) may occur with abrupt withdrawal after long-term therapy or with stress; withdrawal and discontinuation of corticosteroids should be tapered slowly and carefully; patients with HPA axis suppression may require doses of systemic glucocorticosteroids prior to, during, and after unusual stress (eg, surgery).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Immunosuppression may occur; patients may be more susceptible to infections; prolonged use of corticosteroids may also increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral or fungal infections, activate latent opportunistic infections, or limit response to vaccines. Exposure to chickenpox should be avoided; corticosteroids should not be used to treat ocular herpes simplex; use caution in patients with a history of ocular herpes simplex. Corticosteroids should not be used for cerebral malaria or viral hepatitis. Close observation is required in patients with latent tuberculosis and/or TB reactivity; restrict use in active TB (only in conjunction with antituberculosis treatment). Amebiasis should be ruled out in any patient with recent travel to tropical climates or unexplained diarrhea prior to initiation of corticosteroids. Use with great caution in patients with known or suspected",
"     <i>",
"      Strongyloides",
"     </i>",
"     infection.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     May cause osteoporosis (at any age) or inhibition of bone growth in pediatric patients. Use with caution in patients with osteoporosis. In a population-based study of children, risk of fracture was shown to be increased with &gt;4 courses of corticosteroids; underlying clinical condition may also impact bone health and osteoporotic effect of corticosteroids (Leonard, 2006).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Corticosteroid use may cause psychiatric disturbances, including depression, euphoria, insomnia, mood swings, and personality changes. Pre-existing psychiatric conditions may be exacerbated by corticosteroid use. Acute myopathy may occur with high doses, usually in patients with neuromuscular transmission disorders; myopathy may involve ocular and/or respiratory muscles; monitor creatine kinase; recovery may be delayed. Increased IOP may occur, especially with prolonged use; in children, increased IOP has been shown to be dose-dependent and produce a greater IOP in children &lt;6 years than older children (Lam, 2005). Rare cases of anaphylactoid reactions have been reported with corticosteroids.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     High-dose corticosteroids should not be used for the management of traumatic brain injury (an increase in mortality was observed in patients with cranial trauma who received high-dose I.V. methylprednisolone hemisuccinate). Depressions in the skin, due to dermal and/or subdermal atrophy, may occur at the site of methylprednisolone acetate injection; do not exceed recommended dose per injection; avoid injection or leakage into the dermis; avoid injection into deltoid muscle (high incidence of subcutaneous atrophy).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Methylprednisolone",
"     <b>",
"      acetate",
"     </b>",
"     I.M. injection (multiple-dose vial) and the diluent for methylprednisolone",
"     <b>",
"      sodium succinate",
"     </b>",
"     injection contain benzyl alcohol which may cause allergic reactions in susceptible individuals; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; avoid use of methylprednisolone products containing benzyl alcohol in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate, a metabolite of benzyl alcohol, displaces bilirubin from protein binding sites. Benzyl alcohol is also potentially toxic to neural tissue when administered locally. Methylprednisolone",
"     <b>",
"      acetate",
"     </b>",
"     injection may also contain polysorbate 80 (Tween 80&reg;) which may cause allergic reactions in susceptible individuals. In premature neonates, thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported after receiving parenteral products containing polysorbate 80 (Alade, 1986;",
"     <i>",
"      MMWR",
"     </i>",
"     , 1984). Infusion of polysorbate 80-containing solutions through polyvinyl chloride tubing may cause DEHP to leach into the solution; in immature animals, exposure to DEHP may adversely affect the development of the male reproductive tract.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F195422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C8 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F195351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglutethimide: May increase the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: Corticosteroids (Systemic) may enhance the hypokalemic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the bioavailability of Corticosteroids (Oral). Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Corticosteroids (Systemic) may diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Corticosteroids (Oral).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcitriol: Corticosteroids (Systemic) may diminish the therapeutic effect of Calcitriol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Corticosteroids (Systemic).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of MethylPREDNISolone. Management: Consider an alternative corticosteroid. If this combination cannot be avoided, monitor for diminished methylprednisolone effects during carbamazepine treatment, and increased methylprednisolone effects following carbamazepine discontinuation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of MethylPREDNISolone. MethylPREDNISolone may increase the serum concentration of CycloSPORINE (Systemic). MethylPREDNISolone may decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of MethylPREDNISolone. Management: Consider methylprednisolone dose titration and/or adjustments in patients receiving strong CYP3A4 inhibitors (eg, azole antifungals, protease inhibitors) and monitor for  increased steroid related adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estrogen Derivatives: May increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May increase the serum concentration of Corticosteroids (Systemic). The active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of MethylPREDNISolone. Management: Consider an alternative corticosteroid. If this combination cannot be avoided, monitor for diminished methylprednisolone effects during phenytoin treatment, and increased methylprednisolone effects following phenytoin discontinuation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indacaterol: May enhance the hypokalemic effect of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Corticosteroids (Systemic).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May diminish the therapeutic effect of Corticosteroids (Systemic). Mifepristone may increase the serum concentration of Corticosteroids (Systemic). Management: Avoid mifepristone in patients who require long-term corticosteroid treatment of serious illnesses or conditions (e.g., for immunosuppression following transplantation). Corticosteroid effects may be reduced by mifepristone treatment.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mitotane: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): May enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Corticosteroids (Systemic) may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of MethylPREDNISolone. Management: Consider an alternative corticosteroid. If this combination cannot be avoided, monitor for diminished methylprednisolone effects during phenytoin treatment, and increased methylprednisolone effects following phenytoin discontinuation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May enhance the adverse/toxic effect of Corticosteroids (Systemic). Risk of tendon-related side effects, including tendonitis and rupture, may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Corticosteroids (Systemic). Corticosteroids (Systemic) may decrease the serum concentration of Telaprevir. Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Corticosteroids (Systemic) may enhance the anticoagulant effect of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1054009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Systemic use of corticosteroids may require a diet with increased potassium, vitamins A, B",
"     <sub>",
"      6",
"     </sub>",
"     , C, D, folate, calcium, zinc and phosphorus and decreased sodium; grapefruit juice may significantly increase the bioavailability of oral methylprednisolone",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6472614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed with corticosteroids in animal reproduction studies. Methylprednisolone crosses the placenta. Some studies have shown an association between first trimester systemic corticosteroid use and oral clefts; adverse events in the fetus/neonate have been noted in case reports following large doses of systemic corticosteroids during pregnancy. Pregnant women exposed to methylprednisolone for antirejection therapy following a transplant may contact the National Transplantation Pregnancy Registry (NTPR) at 215-955-4820. Women exposed to methylprednisolone during pregnancy for the treatment of an autoimmune disease may contact the OTIS Autoimmune Diseases Study at 877-311-8972.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1053998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, serum glucose, potassium, and calcium and clinical presence of adverse effects. Monitor intraocular pressure (if therapy &gt;6 weeks), linear growth of pediatric patients (with chronic use), assess HPA suppression",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1053989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreases inflammation by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1054005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The time of maximum effects and the duration of these effects is dependent upon the route of administration. See table.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <col align=\"center\" width=\"130\">",
"     </col>",
"     <col align=\"center\" width=\"155\">",
"     </col>",
"     <col align=\"center\" width=\"125\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Route",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Maximum Effect",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Duration",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Oral",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1-2 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         30-36 hours",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         I.M. (acetate)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4-8 days",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1-4 weeks",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Intra-articular",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1 week",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1-5 weeks",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F8097440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adolescents: 1.9 + 0.7 hours (n=6; patients 12-20 years of age; Rouster-Stevens, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: 2.4-3.3 hours (Rohatagi, 1997)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1053997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?14/5/14422?source=see_link\">",
"      see \"Methylprednisolone: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid alcohol; avoid grapefruit juice if taking oral methylprednisolone; limit caffeine. Notify physician if condition being treated persists or worsens; do not decrease or discontinue dose without physician's approval. Avoid exposure to chicken pox or measles, if exposed seek medical advice without delay",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1054007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sodium content of 1 g sodium succinate injection: 2.01 mEq; methylprednisolone sodium succinate 53 mg = methylprednisolone base 40 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Adams A, MacDermott EJ, and Lehman TJ, \"Pharmacotherapy of Lupus Nephritis in Children: A Recommended Treatment Approach,\"",
"      <i>",
"       Drugs",
"      </i>",
"      , 2006, 66(9):1191-207.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/63/17401/abstract-text/16827597/pubmed\" id=\"16827597\" target=\"_blank\">",
"        16827597",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Alade SL, Brown RE, and Paquet A Jr, \"Polysorbate 80 and E-Ferol Toxicity,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1986, 77(4):593-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/63/17401/abstract-text/3960626/pubmed\" id=\"3960626\" target=\"_blank\">",
"        3960626",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Carpenter PA and Macmillan ML, \"Management of Acute Graft-Versus-Host Disease in Children,\"",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 2010, 57(1):273-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/63/17401/abstract-text/20307721/pubmed\" id=\"20307721\" target=\"_blank\">",
"        20307721",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control (CDC), \"Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Recommendations From CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009a, 58(RR-4):1-207.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/63/17401/abstract-text/19357635/pubmed\" id=\"19357635\" target=\"_blank\">",
"        19357635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control (CDC), \"Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-Exposed and HIV-Infected Children: Recommendations From CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/63/17401/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control (CDC), \"Unusual Syndrome With Fatalities Among Premature Infants: Association With a New Intravenous Vitamin E Product,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 1984, 33(14):198-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/63/17401/abstract-text/6423951/pubmed\" id=\"6423951\" target=\"_blank\">",
"        6423951",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Consortium for Spinal Cord Medicine, \"Early Acute Management in Adults With Spinal Cord Injury: A Clinical Practice Guideline for Health-Care Professionals,\"",
"      <i>",
"       J Spinal Cord Med",
"      </i>",
"      , 2008, 31(4):403-79.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/63/17401/abstract-text/18959359/pubmed\" id=\"18959359\" target=\"_blank\">",
"        18959359",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lam DS, Fan DS, Ng JS, et al, \"Ocular Hypertensive and Anti-Inflammatory Responses to Different Dosages of Topical Dexamethasone in Children: A Randomized Trial,\"",
"      <i>",
"       Clin Experiment Ophthalmol",
"      </i>",
"      , 2005, 33(3):252-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/63/17401/abstract-text/15932528/pubmed\" id=\"15932528\" target=\"_blank\">",
"        15932528",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leonard MB, \"Glucocorticoid-Induced Osteoporosis in Children: Impact of the Underlying Disease,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2007, 119 Suppl 2:S166-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/63/17401/abstract-text/17332238/pubmed\" id=\"17332238\" target=\"_blank\">",
"        17332238",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marks SD and Tullus K, \"Modern Therapeutic Strategies for Paediatric Systemic Lupus Erythematosus and Lupus Nephritis,\"",
"      <i>",
"       Acta Paediatr",
"      </i>",
"      , 2010, 99(7):967-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/63/17401/abstract-text/20222881/pubmed\" id=\"20222881\" target=\"_blank\">",
"        20222881",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Asthma Education and Prevention Program (NAEPP), &ldquo;Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma,&rdquo;",
"      <i>",
"       Clinical Practice Guidelines",
"      </i>",
"      , National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007; available at file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ponticelli C, Glassock RJ, and Moroni G, &ldquo;Induction and Maintenance Therapy in Proliferative Lupus Nephritis,&rdquo;",
"      <i>",
"       J Nephrol",
"      </i>",
"      , 2010, 23(1):9-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/63/17401/abstract-text/20091481/pubmed\" id=\"20091481\" target=\"_blank\">",
"        20091481",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rohatagi S, Barth J, M&ouml;llmann H, et al, \"Pharmacokinetics of Methylprednisolone and Prednisolone After Single and Multiple Oral Administration,\"",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1997, 37(10):916-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/63/17401/abstract-text/9505983/pubmed\" id=\"9505983\" target=\"_blank\">",
"        9505983",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rouster-Stevens KA, Gursahaney A, Ngai KL, et al, \"Pharmacokinetic Study of Oral Prednisolone Compared With Intravenous Methylprednisolone in Patients With Juvenile Dermatomyositis,\"",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 2008, 59(2):222-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/63/17401/abstract-text/18240180/pubmed\" id=\"18240180\" target=\"_blank\">",
"        18240180",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12601 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-77.94.48.4-3E90DA3289-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_63_17401=[""].join("\n");
var outline_f16_63_17401=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15254327\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195382\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195383\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053999\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053992\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195358\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195342\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054003\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195435\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9522886\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054002\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195438\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195434\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054006\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053991\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053990\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195422\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195351\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054009\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6472614\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053998\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053989\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054005\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097440\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053997\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054007\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12601\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12601|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=related_link\">",
"      Methylprednisolone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?14/5/14422?source=related_link\">",
"      Methylprednisolone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_63_17402="Initial treatment of mantle cell lymphoma";
var content_f16_63_17402=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initial treatment of mantle cell lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/63/17402/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/63/17402/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/63/17402/contributors\">",
"     Jonathan W Friedberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/63/17402/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/63/17402/contributors\">",
"     Andrew Lister, MD, FRCP, FRCPath, FRCR",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/63/17402/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/63/17402/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/63/17402/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mantle cell lymphoma (MCL), one of the B cell non-Hodgkin lymphomas (NHLs), has a variable course. A minority of patients with this disorder may survive untreated for many years. However, in more patients, MCL assumes a more virulent character, akin to that of an aggressive NHL variant.",
"   </p>",
"   <p>",
"    The initial treatment of MCL will be discussed here. Clinical and pathologic features, diagnosis, and differential diagnosis of this disorder are discussed separately, as is the treatment of relapsed or refractory MCL. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/29/30169?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of mantle cell lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1065?source=see_link\">",
"     \"Treatment of relapsed or refractory mantle cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H413544\">",
"    <span class=\"h1\">",
"     ONCOLOGIC EMERGENCIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oncologic emergencies and treatment-related hematologic toxicities are common in the aggressive NHLs. Clinicians must always be alert to their potential presence, and be prepared to deal with them urgently and effectively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\", section on 'Oncologic emergencies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Emergencies that are more common in patients with MCL include hyperleukocytosis and intestinal obstruction or intussusception:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Involvement of the gastrointestinal tract is common in MCL, occasionally presenting with multiple intestinal polyposis and intestinal obstruction or intussusception. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/38/8807?source=see_link\">",
"       \"Small bowel obstruction: Clinical manifestations and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8714?source=see_link\">",
"       \"Clinical presentation and diagnosis of primary gastrointestinal lymphomas\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Uncommonly, patients with MCL may have marked lymphocytosis mimicking prolymphocytic leukemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/7/19576?source=see_link\">",
"       \"Hyperleukocytosis and leukostasis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;While most patients with MCL who do not begin therapy will die of their disease within a few years, a small proportion, increasingly better defined, may remain stable for years. These occasional patients with low tumor burden (",
"    <a class=\"graphic graphic_table graphicRef73699 \" href=\"UTD.htm?36/59/37819\">",
"     table 1",
"    </a>",
"    ), low-risk (",
"    <a class=\"graphic graphic_table graphicRef70850 \" href=\"UTD.htm?17/21/17757\">",
"     table 2",
"    </a>",
"    ) disease may have an indolent course, managed by observation, splenectomy, or treatment with alkylating agents analogous to the treatment of patients with small lymphocytic lymphoma or chronic lymphocytic leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9865?source=see_link\">",
"     \"Initial treatment of limited stage (I/II) follicular lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29352?source=see_link\">",
"     \"Overview of the treatment of chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While we know that a small proportion of these patients will progress slowly, it is very difficult to identify these patients at the time of diagnosis. As an example, a retrospective analysis of 97 patients with asymptomatic MCL treated at a single institution found that approximately one-third of patients were observed for more than three months before initiating therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/5\">",
"     5",
"    </a>",
"    ]. Treatment was postponed for more than one year in 14 patients and more than five years in three patients. This suggests that some patients with MCL may have an indolent course; however, on multivariate analysis, clinical characteristics including age, stage, World Health Organization performance status, extranodal status, and lactate dehydrogenase (LDH) level were not able to predict which patients would progress slowly. Clinicians differ in their management of patients expected to have a more indolent course. While some advocate watch and wait, others feel this is the group that might benefit from aggressive therapies. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Overview'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The Ki-67 index, a measure of tumor proliferative activity, may provide some insight into which patients will be more likely to progress. As an example, a retrospective study of 249 patients with advanced-stage MCL enrolled in prospective clinical trials of CHOP or R-CHOP found significantly longer median overall survival times in patients with tumors demonstrating a Ki-67 index less than 10 percent when compared with those with higher Ki-67 indices [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/6\">",
"     6",
"    </a>",
"    ]. Survival in patients with Ki-67 &lt;10 percent was akin to those with indolent lymphomas.",
"   </p>",
"   <p>",
"    In our clinical experience, those with more indolent tumors comprise a small percentage of patients with MCL and typically present with lymphocytosis, a few enlarged lymph nodes, splenomegaly, and a Ki-67 index &lt;10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite this, the long-term outlook for most patients with MCL is poor with median overall survival times with treatment of three to five years. There is no evidence that currently available treatment programs are curative [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/8\">",
"     8",
"    </a>",
"    ]. However, patients with advanced or symptomatic disease are treated with combination chemotherapy to decrease tumor bulk and alleviate symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/29/30169?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of mantle cell lymphoma\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PRETREATMENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pretreatment evaluation both determines the bulk of disease and provides information about the individual's comorbidities that are likely to have an impact on treatment options. In addition to a history and physical examination, it is our practice to perform the following pretreatment studies in patients with MCL:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laboratory studies include a complete blood count with differential, chemistries with liver and renal function and electrolytes, LDH, hepatitis B, HIV, and uric acid. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=see_link\">",
"       \"Hepatitis B virus reactivation associated with immunosuppression\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Unilateral bone marrow biopsy is recommended for all patients in addition to visual inspection of the blood smear and consideration of flow cytometry of the peripheral blood.",
"     </li>",
"     <li>",
"      We perform a lumbar puncture on patients with the MCL blastic variant or those with central nervous system symptoms. When performed, cerebrospinal fluid should be sent for both cytology and flow cytometry.",
"     </li>",
"     <li>",
"      A contrast-enhanced computed tomography (CT) scan of the chest, abdomen, and pelvis should be performed. This study provides critical information on the measurement of disease prior to treatment, and aids in staging. Although MCL is routinely FDG-avid, results of pre-treatment positron emission tomography (PET) scans are unlikely to change management [",
"      <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/9-11\">",
"       9-11",
"      </a>",
"      ]. As such, PET scanning is reserved for use in clinical trials [",
"      <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/12\">",
"       12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=see_link&amp;anchor=H13#H13\">",
"       \"Initial evaluation and staging of non-Hodgkin lymphoma\", section on 'Routine imaging studies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Upper endoscopy and colonoscopy are performed for patients with gastrointestinal symptoms; as asymptomatic gastrointestinal involvement is common, we also suggest colonoscopy for all asymptomatic patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8714?source=see_link&amp;anchor=H6#H6\">",
"       \"Clinical presentation and diagnosis of primary gastrointestinal lymphomas\", section on 'Gastric lymphoma'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A study of cardiac ejection fraction (eg, echocardiogram or MUGA) should be performed if anthracyclines are used. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=see_link\">",
"       \"Cardiotoxicity of anthracycline-like chemotherapy agents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Men and women of childbearing potential should receive counseling about the potential effect of treatment on their fertility and options for fertility-preserving measures. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=see_link\">",
"       \"Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    General approaches to the diagnostic work-up and staging of non-Hodgkin lymphoma are presented separately (",
"    <a class=\"graphic graphic_table graphicRef73699 \" href=\"UTD.htm?36/59/37819\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=see_link\">",
"     \"Initial evaluation and staging of non-Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INITIAL TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, most patients require treatment of MCL at the time of diagnosis. While occasional patients with low stage, low-risk disease may have an indolent course that can be observed initially, combination chemotherapy plus immunotherapy (ie, chemoimmunotherapy) remains the main treatment modality. Surgery is usually not employed, but may be of value in patients with MCL involving the gastrointestinal tract presenting with bowel obstruction or uncontrollable bleeding, usually from extensive colonic polyposis. Likewise, radiation therapy is usually reserved for palliation. There are very limited data on the use of myeloablative allogeneic HCT in this patient population. Nonmyeloablative allogeneic HCT is under investigation in the relapsed setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3930?source=see_link&amp;anchor=H21#H21\">",
"     \"Management of gastrointestinal lymphomas\", section on 'Mantle cell lymphoma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1065?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of relapsed or refractory mantle cell lymphoma\", section on 'Radiation therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is a diversity of clinical practice and ambiguity surrounding the preferred treatment approach for patients with MCL. Whenever possible, young, otherwise healthy patients with advanced, symptomatic MCL should be referred to a center offering a",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/\">",
"     clinical trial",
"    </a>",
"    . Outside of a clinical trial, treatment options include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Conventional chemoimmunotherapy (eg, R-CHOP, R-CVP, BR) alone or followed by maintenance",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      &mdash; This approach is appropriate for patients who are not candidates for autologous hematopoietic cell transplantation (HCT). Although it is not curative, a majority of patients will attain a complete response. Maintenance rituximab appears to prolong progression-free survival (PFS) and may improve overall survival (OS). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Conventional chemoimmunotherapy'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H247521657\">",
"       'Maintenance therapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Conventional chemoimmunotherapy followed by high dose chemotherapy and autologous HCT",
"      </strong>",
"      &mdash; This is our preferred treatment for patients who are eligible for HCT. The addition of HCT improves PFS and may improve OS. Non-randomized studies suggest that this approach is as effective and less toxic than R-Hyper-CVAD. (See",
"      <a class=\"local\" href=\"#H1967069\">",
"       'Autologous transplantation'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Intensive chemoimmunotherapy (eg, R-Hyper-CVAD) alone",
"      </strong>",
"      &mdash; Non-randomized, single-center trials suggest improved survival in young adults (&lt;60 years) treated with R-Hyper-CVAD when compared with those treated with conventional chemotherapy alone. However, studies in cooperative group settings have not confirmed these benefits and have demonstrated significant toxicity with this regimen. Importantly, the toxicity excludes its use in older adults (ie, &gt;65 years) and limits its use in individuals between the ages of 60 and 65 years. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Hyper-CVAD'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These approaches have never been directly compared in a randomized trial. While some prospective, non-randomized trials have suggested longer median overall survival rates with a more aggressive treatment approach (either R-Hyper-CVAD or HCT), these are also associated with a higher incidence of treatment related toxicities. The uncertainty surrounding the benefits of more aggressive therapy was highlighted by a single-institution retrospective analysis of 111 patients with newly diagnosed MCL, 70 percent of whom were treated with conventional chemotherapy (R-CHOP-like or CHOP-like regimens) without HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/13\">",
"     13",
"    </a>",
"    ]. Median overall survival was seven years. The three and five year overall survival rates of 86 and 66 percent respectively, were similar to those seen in prospective studies of Hyper-CVAD.",
"   </p>",
"   <p>",
"    The evidence supporting these various approaches is described in the following sections. In addition, we offer guidance on the selection of therapy for different patient populations based upon our interpretation of the literature and experience. (See",
"    <a class=\"local\" href=\"#H4668248\">",
"     'Our treatment approach'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Role for rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;The monoclonal CD20 antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    is known to be beneficial in the initial treatment of several types of non-Hodgkin lymphoma, including MCL. Initial comparisons with historical controls suggested that rituximab may play a role in the treatment of MCL, while prospective randomized trials have had mixed results [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/14-21\">",
"     14-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 2007 meta-analysis of the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    plus chemotherapy for patients with indolent NHL or MCL found that patients treated with rituximab plus chemotherapy had superior overall survival, response, and disease control than patients treated with chemotherapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/8,22\">",
"     8,22",
"    </a>",
"    ]. However, only three small studies were available for MCL in this study. A subsequent retrospective analysis of the Surveillance Epidemiology and End Result (SEER) and Medicare databases of 638 older adults with MCL who received initial chemotherapy with (64 percent) or without rituximab reported that the addition of rituximab was associated with superior median survival (37 versus 27 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/23\">",
"     23",
"    </a>",
"    ]. On multivariate analysis, the addition of rituximab was associated with lower rates of both all-cause (hazard ratio [HR] 0.58; 95% CI 0.41-0.82) and cancer-specific mortality (HR 0.56, 95% CI 0.37-0.84) at two years.",
"   </p>",
"   <p>",
"    For patients with MCL, we recommend the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    to combination chemotherapy rather than chemotherapy alone. This is primarily due to the low risk of toxicity related to the addition of rituximab and a possible but uncertain benefit in overall survival. Rituximab can be incorporated into either conventional chemotherapy regimens or aggressive treatment programs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1967967\">",
"    <span class=\"h2\">",
"     Induction chemoimmunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Induction chemoimmunotherapy used for patients with MCL can be conceptually divided into two groups based upon intensity:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Conventional chemoimmunotherapy",
"      </strong>",
"      &mdash; Conventional chemotherapy includes regimens such as R-CHOP, R-CVP, and the off-label use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/20/32071?source=see_link\">",
"       bendamustine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      . We use conventional chemoimmunotherapy for induction in most patients with MCL. Patients who attain an at least partial response following conventional chemoimmunotherapy are considered for consolidation with autologous hematopoietic cell transplantation (HCT). Those who are not candidates for HCT are considered for maintenance therapy with rituximab. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Conventional chemoimmunotherapy'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/50/19241?source=see_link\">",
"       \"Determining eligibility for autologous hematopoietic cell transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       R-Hyper-CVAD",
"      </strong>",
"      &mdash; R-Hyper-CVAD employs",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      plus hyperfractionated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      , alternating with high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      . R-Hyper-CVAD is used by some clinicians for the treatment of younger (&lt;60 years) patients without comorbidities, especially those with disease that displays characteristics that suggest a low likelihood of response to conventional chemoimmunotherapy (ie, blastic variant of MCL or a high IPI score or a high MIPI score). While non-randomized trials from experienced centers have suggested improved outcomes with R-Hyper-CVAD, it is associated with a higher incidence of treatment related toxicities. Autologous HCT and maintenance rituximab have not demonstrated a benefit in patients initially treated with R-Hyper-CVAD. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Hyper-CVAD'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Conventional chemoimmunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conventional chemoimmunotherapy is our preferred initial treatment for most patients with MCL. With conventional chemoimmunotherapy alone, the overall response rate is approximately 80 percent; the median overall survival in most studies ranges from three to four years with less than 15 percent of patients alive at five years [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/18,24,25\">",
"     18,24,25",
"    </a>",
"    ]. Subsequent treatment with consolidation or maintenance therapy appears to prolong remission and may improve survival. A choice among various conventional regimens depends upon patient characteristics and physician comfort. In general, we prefer R-CHOP or the off-label use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/20/32071?source=see_link\">",
"     bendamustine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (BR) based on acceptable toxicity profiles. R-CVP is an acceptable alternative. The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    -based regimens (eg, FCR) is limited due to high toxicity in this population.",
"   </p>",
"   <p>",
"    Although R-CHOP has not been compared directly with R-CVP, a randomized trial found no survival difference when CHOP without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    was compared with CVP without rituximab [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/24\">",
"     24",
"    </a>",
"    ]. A randomized study comparing BR with R-CHOP reported that BR was less toxic and produced superior progression-free survival and similar survival rates [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/26\">",
"     26",
"    </a>",
"    ]. BR has not been compared with R-CVP.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       R-CHOP",
"      </strong>",
"      (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ) (",
"      <a class=\"graphic graphic_table graphicRef63586 \" href=\"UTD.htm?22/2/22574\">",
"       table 3",
"      </a>",
"      ) &mdash; The most common severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      side effect is granulocytopenia (60 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/18,27\">",
"       18,27",
"      </a>",
"      ]. Other common side effects are generally mild to moderate alopecia, nausea, vomiting, and infusion-related reactions. Reported overall and complete response rates are approximately 85 and 35 percent, respectively. The estimated rates of two- and four-year survival are 75 and 60 percent, respectively. Median survival in retrospective studies has been as long as seven years [",
"      <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/13\">",
"       13",
"      </a>",
"      ]. In a phase II trial, the addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      to R-CHOP in 36 patients resulted in overall and complete response rates of 81 and 64 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/28\">",
"       28",
"      </a>",
"      ]. Rates of progression-free and overall survival at two years were 44 and 86 percent, respectively.",
"     </li>",
"     <li>",
"      <strong>",
"       BR",
"      </strong>",
"      (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/20/32071?source=see_link\">",
"       bendamustine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      ) &mdash; Single arm prospective trials evaluating the combination of bendamustine plus rituximab in relapsed or refractory MCL have reported overall response rates of 75 to 90 percent. A randomized trial comparing bendamustine (90",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      days 1 and 2) plus rituximab (375",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      day 1) every 28 days for six cycles versus standard R-CHOP for six cycles in 514 patients with advanced follicular, indolent, and mantle cell lymphoma (18 percent), suggested that BR resulted in superior median progression-free survival (69.5 versus 31.2 months, hazard ratio 0.58, 95% CI 0.44-0.74) for all histologic subtypes except marginal zone lymphoma with less toxicity, including lower rates of grade 3 and 4 neutropenia (29 versus 69 percent) and leukocytopenia (37 versus 72 percent), fewer infectious episodes (37 versus 50 percent), less paresthesia (7 versus 29 percent), less stomatitis (6 versus 19 percent), and no alopecia [",
"      <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/26\">",
"       26",
"      </a>",
"      ]. There was no difference in OS at a median follow-up of 45 months. The number of second malignancies was similar between the two treatment arms (20 versus 23 cases). The long-term toxicity profile and impact on future treatments, including hematopoietic stem cell collection, are unknown. &nbsp;(See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1065?source=see_link&amp;anchor=H5#H5\">",
"       \"Treatment of relapsed or refractory mantle cell lymphoma\", section on 'Bendamustine plus rituximab'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       R-CVP",
"      </strong>",
"      (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ) &mdash; Side effects are generally mild with gastrointestinal toxicities and peripheral neuropathy being most common [",
"      <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/13,29\">",
"       13,29",
"      </a>",
"      ]. Severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      neutropenia occurs in approximately 25 percent. A prospective randomized trial that compared CHOP with CVP in 63 patients with newly diagnosed MCL reported no difference in rates of complete response or overall survival, which were approximately 50 percent and 35 months, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       R-CHOP plus R-DHAP",
"      </strong>",
"      (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      , high dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      ) &mdash; A phase II trial from the Groupe d&rsquo;Etude des Lymphomes de l&rsquo;Adulte evaluated the use of every three week sequential chemotherapy consisting of CHOP (two cycles), R-CHOP (one cycle), and R-DHAP (three cycles), plus intrathecal chemotherapy, followed by autologous hematopoietic cell transplantation in 60 younger adults (&lt;66 years) with stage III or IV MCL [",
"      <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/30\">",
"       30",
"      </a>",
"      ]. Significant nonhematologic toxicities included renal insufficiency, neurologic toxicity, and one sudden cardiac death. There were 12 second malignancies. Following induction, overall and complete response rates were 87 and 57 percent, respectively. At a median follow-up of 67 months, estimated median event-free survival was 84 months with estimated rates of event-free and overall survival at five years of 64 and 75 percent, respectively. Preliminary results of a randomized phase III trial comparing this regimen with six cycles of R-CHOP suggest a survival benefit from R-CHOP plus R-DHAP [",
"      <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other less widely studied conventional chemotherapy regimens that have been used for the treatment of MCL include the NORDIC regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/32,33\">",
"     32,33",
"    </a>",
"    ], the CALGB regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/34\">",
"     34",
"    </a>",
"    ], sequential",
"    <span class=\"nowrap\">",
"     R-CHOP/R-ICE",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/35\">",
"     35",
"    </a>",
"    ], and alternating",
"    <span class=\"nowrap\">",
"     R-CHOP/R-DHAP",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/30,36\">",
"     30,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anthracycline-based regimens, such as R-CHOP, are frequently used, but the additional benefit gained by including an anthracycline is not entirely clear. Interest in using anthracycline-based regimens was initially driven by a retrospective analysis of 65 patients with MCL, which noted a survival advantage with anthracycline-containing regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/37\">",
"     37",
"    </a>",
"    ]. Subsequent randomized trials have had mixed results with two demonstrating no survival advantage when CHOP was compared with the non-anthracycline containing regimens CVP and MCP (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/24,25\">",
"     24,25",
"    </a>",
"    ], and another demonstrating a survival advantage of R-CHOP over the combination of FCR (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective randomized trial that compared CHOP with CVP in 63 patients with newly diagnosed MCL reported no difference in rates of complete response or overall survival, which were approximately 50 percent and 35 months, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A randomized trial compared CHOP with MCP in 86 patients with newly diagnosed MCL [",
"      <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/25\">",
"       25",
"      </a>",
"      ]. The overall response rate and overall survival times in the two arms were similar at approximately 80 percent and 4.6 years, respectively. The proportion of patients successfully undergoing peripheral blood stem cell collection was significantly lower after MCP (44 versus 93 percent).",
"     </li>",
"     <li>",
"      A randomized trial compared R-CHOP with FCR in 560 older adults (&gt;60 years) with newly diagnosed MCL [",
"      <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/27\">",
"       27",
"      </a>",
"      ]. R-CHOP resulted in similar complete remission rates (34 versus 40 percent), but lower hematologic toxicity and higher rates of overall survival at four years (62 versus 47 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These studies suggest that R-CHOP and R-CVP are both acceptable regimens for the treatment of newly diagnosed MCL. In contrast, FCR appears to be more toxic and less efficacious than R-CHOP. This, in combination with other studies that have suggested that FCR may impair subsequent peripheral blood stem cell collection, supports our preference of R-CHOP over FCR in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For most patients, we suggest conventional chemoimmunotherapy, such as R-CHOP or R-CVP, rather than FCR or more intensive chemoimmunotherapy (eg, Hyper-CVAD). The off-label use of BR is an acceptable alternative, although there is a paucity of data regarding its impact on stem cell collection or long-term safety. This preference places a low value on the potential, but unproven, benefit of more aggressive chemoimmunotherapy regimens (eg, Hyper-CVAD) and a high value on the known, more tolerable, side effect profiles of conventional chemoimmunotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Hyper-CVAD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intensive chemotherapy programs, such as those used in other highly aggressive NHL variants (eg, Burkitt lymphoma, lymphoblastic lymphoma), with or without subsequent hematopoietic cell transplantation (HCT), have been employed in an attempt to obtain better long-term disease control. However, at present there is no evidence that currently available aggressive treatment programs are curative [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Perhaps the most commonly used aggressive induction therapy regimen is Hyper-CVAD, which employs hyperfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , alternating with high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    , with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hematopoietic cell transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/17,41-43\">",
"     17,41-43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initial reports on the use of this regimen came from two prospective trials, both from a single institution [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/16,17,42\">",
"     16,17,42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective phase II trial that included a mixture of 45 patients with newly diagnosed or previously treated MCL evaluating Hyper-CVAD followed by autologous or allogeneic HCT reported a complete response rate after Hyper-CVAD of 38 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/17\">",
"       17",
"      </a>",
"      ]. Thirty-four patients (75 percent) proceeded to HCT as planned (26 autologous and 8 allogeneic). The results for previously untreated patients were encouraging, with estimated five-year overall and disease-free survival rates of 77 and 43 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second prospective trial evaluated six cycles of Hyper-CVAD plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      in 97 evaluable patients with previously untreated MCL [",
"      <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/16\">",
"       16",
"      </a>",
"      ]. The rate of complete response plus unconfirmed complete response was 87 percent. None of the patients went on to receive HCT. At a median follow-up of 40 months, three-year failure-free and overall survival rates were 64 and 82 percent, respectively, without a plateau in the curves. Twenty-nine percent of patients were not able to complete the planned number of treatment cycles due to toxicity. There were eight deaths including four cases (three fatal) of treatment-related acute myeloid",
"      <span class=\"nowrap\">",
"       leukemia/myelodysplastic",
"      </span>",
"      syndrome",
"      <span class=\"nowrap\">",
"       (AML/MDS),",
"      </span>",
"      which developed while the patients were in complete remission.",
"      <br/>",
"      <br/>",
"      A subsequent report of this trial with a median follow-up of eight years observed that the median overall survival had still not been reached, while the median time to failure was 4.6 years [",
"      <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/44\">",
"       44",
"      </a>",
"      ]. On subset analysis, patients 65 years or younger had significantly higher rates of overall survival at eight years (68 versus 33 percent) when compared with older patients. Since the prior publication, an additional patient developed MDS thereby increasing the rate of",
"      <span class=\"nowrap\">",
"       AML/MDS",
"      </span>",
"      to 5 percent. No additional late toxicities were observed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Attempts to replicate this regimen in a cooperative group setting have highlighted the difficulty of administration due to toxicity. Importantly, the toxicity excludes its use in older adults (ie, &gt;65 years) and limits its use in individuals between the ages of 60 and 65 years. Individuals age 60 to 65 years require dose modifications of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    , which may limit efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a multicenter prospective European trial, 60 patients with MCL who underwent initial treatment with hyper-CVAD plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      with complete and overall response rates of 72 and 83 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/45\">",
"       45",
"      </a>",
"      ]. However, 63 percent of patients were unable to complete the planned treatment course, mostly due to toxicity. Half of the patients experienced severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicity, the majority of which were hematologic and infectious. After a median follow-up of 46 months, overall and failure-free survival at two years were 86 and 61 percent, respectively.",
"     </li>",
"     <li>",
"      Although only reported in abstract form, a SWOG prospective phase II trial R-Hyper-CVAD in 49 patients from multiple institutions also reported a two-year failure-free survival rate of 63 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/46\">",
"       46",
"      </a>",
"      ]. In this setting, 48 percent of patients were unable to complete the planned treatment regimen secondary to toxicity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While the results from the single institution, uncontrolled trials are promising, R-Hyper-CVAD has many associated toxicities and has not been directly compared with conventional chemotherapy. In addition, as the cooperative group studies suggest, like with many other regimens, excellent patient outcomes in a single institution do not necessarily translate to excellent outcomes in practice at other institutions. Clinical trials are evaluating modified versions of R-Hyper-CVAD that incorporate other agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    ) in an attempt to reduce toxicity and improve response rates [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4668248\">",
"    <span class=\"h2\">",
"     Our treatment approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whenever possible, young, otherwise healthy patients with advanced, symptomatic MCL should be referred to a center offering a clinical trial. Outside of a clinical trial, a choice between treatment options depends upon patient characteristics (eg, age or comorbidities), patient preferences, side effect profiles, and the physician's comfort with the various regimens. The International Prognostic Index (IPI) (",
"    <a class=\"graphic graphic_table graphicRef70850 \" href=\"UTD.htm?17/21/17757\">",
"     table 2",
"    </a>",
"    ) or the Mantle cell lymphoma International Prognostic Index (",
"    <a class=\"external\" href=\"file://www.european-mcl.net/en/clinical_mipi.php\">",
"     MIPI",
"    </a>",
"    ) score (",
"    <a class=\"graphic graphic_table graphicRef86535 \" href=\"UTD.htm?38/12/39116\">",
"     table 4",
"    </a>",
"    ) may help to assimilate some of this information. The following are guidelines based upon our practice, which tends to favor the less aggressive treatment approaches; however, more aggressive treatment approaches used by other expert clinicians would also be acceptable. Eligibility for autologous HCT varies across countries and institutions. Details regarding HCT eligibility are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/50/19241?source=see_link\">",
"     \"Determining eligibility for autologous hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The occasional patient with clinically indolent, low-risk disease may have an indolent course that can be observed initially. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications for treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Young patients (eg, &lt;60 years) with a good performance status (eg, ECOG &lt;2 (",
"      <a class=\"graphic graphic_table graphicRef72901 \" href=\"UTD.htm?9/15/9467\">",
"       table 5",
"      </a>",
"      )) are candidates for treatment with either Hyper-CVAD alone or conventional chemoimmunotherapy followed by high dose chemotherapy and autologous HCT. For such patients, we offer induction with conventional chemoimmunotherapy rather than Hyper-CVAD. In general, we prefer R-CHOP or BR based on acceptable toxicity profiles and our experience with these regimens. R-CVP is an acceptable alternative. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Conventional chemoimmunotherapy'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      For older adults with a good performance status, we offer induction with conventional chemotherapy followed by either autologous HCT or maintenance",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      , depending upon HCT eligibility. We do not consider Hyper-CVAD to be an acceptable option for this population, largely due to toxicity that severely limits the ability to administer this regimen to patients in this age group [",
"      <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/45,46,48\">",
"       45,46,48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This general approach places a high value on the potential improvement in progression-free and overall survival with more intensive therapy (ie, Hyper-CVAD or HCT) while trying to avoid the high rates of toxicity associated with Hyper-CVAD in the cooperative group setting. It also places a high value on the potential benefit of maintenance",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    when intensive therapy is not an option. Older adults who wish to avoid potential toxicities of maintenance rituximab may choose treatment with conventional chemoimmunotherapy alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     RESPONSE EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;One month following the completion of planned therapy (or sooner if the outcome is unfavorable), the response to treatment should be documented by history, physical examination, laboratory studies (complete blood count, lactate dehydrogenase, and biochemical profile), and computed tomography (CT) scan. Studies evaluating positron emission tomography (PET) in the response evaluation of patients with MCL have had mixed results [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/9,11,12\">",
"     9,11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because MCL can involve multiple sites within the gastrointestinal tract, National Comprehensive Cancer Network (NCCN) recommends that both upper endoscopy and colonoscopy be performed if not done as part of the initial diagnostic evaluation to assess response to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/49\">",
"     49",
"    </a>",
"    ]. However, this approach has not been evaluated prospectively, and there may be select cases in which such examinations have sufficiently low yield to make them unnecessary. Similarly, patients found to have gastrointestinal involvement at the time of diagnosis should be considered for repeat endoscopy at the time of response evaluation to re-assess areas of prior disease. This is of particular importance for patients being considered for autologous hematopoietic cell transplantation after attainment of a complete remission. (See",
"    <a class=\"local\" href=\"#H1967069\">",
"     'Autologous transplantation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Using information gathered from the history, physical, and CT scan, disease response is determined by the International Workshop Criteria (IWC) (",
"    <a class=\"graphic graphic_table graphicRef64921 \" href=\"UTD.htm?29/27/30140\">",
"     table 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A complete remission has been achieved if all of the following criteria are met [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/50\">",
"     50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is no evidence of disease or disease-related symptoms on history and physical examination.",
"     </li>",
"     <li>",
"      All lymph nodes are normal in size by CT criteria.",
"     </li>",
"     <li>",
"      The spleen and liver are non-palpable and without nodules.",
"     </li>",
"     <li>",
"      If a pretreatment bone marrow biopsy was positive, a repeat bone marrow biopsy must be negative. If morphologically indeterminate, immunohistochemistry should be negative.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment options for patients who achieve a partial remission include second line chemotherapy regimens, high dose therapy with autologous hematopoietic cell transplantation, allogeneic transplantation, or enrollment in a clinical trial of investigational agents. These are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1065?source=see_link\">",
"     \"Treatment of relapsed or refractory mantle cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1966877\">",
"    <span class=\"h1\">",
"     CONSOLIDATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consolidation therapy refers to the administration of a finite amount of additional treatment following an initial partial or complete response to induction chemotherapy in an attempt to deepen the response and prolong remission. Autologous hematopoietic cell transplantation (HCT) is a form of consolidation therapy that is commonly employed in MCL. Autologous HCT appears to improve outcomes following initial therapy with conventional chemoimmunotherapy (eg, R-CHOP, R-CVP, BR). In contrast, autologous HCT has not demonstrated a benefit in patients initially treated with more intensive chemoimmunotherapy, such as R-Hyper-CVAD [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective analysis of 167 younger adults (&lt;65 years) with newly diagnosed MCL treated at NCCN centers with one of the following approaches: R-Hyper-CVAD alone (50 percent), R-Hyper-CVAD followed by HCT (13 percent), R-CHOP followed by HCT (20 percent), or R-CHOP alone (17 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/48\">",
"     48",
"    </a>",
"    ]. When compared with R-CHOP alone, treatment that incorporated R-Hyper-CVAD or HCT resulted in superior progression-free and overall survival. The addition of HCT after induction with R-Hyper-CVAD did not appear to improve outcomes.",
"   </p>",
"   <p>",
"    Clinical trials are investigating other forms of consolidation (eg, radiation therapy, anti-CD20 radioimmunoconjugates) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. As an example, a phase II trial evaluating four cycles of R-CHOP followed by infusion of the anti-CD20 radioimmunoconjugate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/30/40422?source=see_link\">",
"     ibritumomab",
"    </a>",
"    in 56 patients with previously untreated MCL reported overall and complete response rates of 83 and 55 percent, respectively, with an estimated five-year survival of 73 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/51\">",
"     51",
"    </a>",
"    ]. We consider consolidation with radioimmunoconjugates to be investigational.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1967069\">",
"    <span class=\"h2\">",
"     Autologous transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have investigated the role of myeloablative chemotherapy followed by autologous hematopoietic cell",
"    <span class=\"nowrap\">",
"     transplantation/rescue",
"    </span>",
"    (HCT) after initial response to induction chemotherapy in MCL, and this has become common practice at many institutions. So far, autologous HCT has not been shown to prolong overall survival over combination chemotherapy alone and is not curative in patients with advanced MCL, with a pattern of late relapse in the majority of patients so treated [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Five-year overall survival rates with this approach have ranged from 50 to 75 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/32-34,53-60\">",
"     32-34,53-60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A prospective trial of 122 patients &lt;65 years of age with advanced stage MCL randomly assigned patients to treatment with autologous HCT or maintenance therapy with interferon alpha after achievement of complete or partial remission following CHOP-like induction therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/55\">",
"     55",
"    </a>",
"    ]. At a median follow-up of 25 to 34 months, median progression-free survival was significantly longer in the patients receiving HCT (39 versus 17 months), although there was no significant difference in overall survival at two years (86 versus 82 percent).",
"   </p>",
"   <p>",
"    The following is a survey of other retrospective and prospective studies that have evaluated this approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective, registry-based study of 195 patients receiving an autologous HCT for MCL found five-year overall and progression-free survivals of 50 and 33 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/57\">",
"       57",
"      </a>",
"      ]. Disease status at the time of HCT was the most significant factor affecting survival; patients with chemosensitive disease but not in first CR were three times more likely to die than those transplanted in first CR.",
"     </li>",
"     <li>",
"      Another single-center retrospective analysis of 118 consecutive patients with MCL who received autologous HCT for MCL reported rates of overall and progression-free survival at five-years of 57 and 48 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/61\">",
"       61",
"      </a>",
"      ]. The Mantle Cell Lymphoma International Prognostic Index (MIPI) at the time of diagnosis was the strongest predictor of survival after HCT (hazard ratio 3.5; 95% CI 2.1-6.0). In comparison, increased intensity of the induction regimen prior to HCT was not associated with improved survival after HCT. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/29/30169?source=see_link&amp;anchor=H14#H14\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of mantle cell lymphoma\", section on 'Prognosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A prospective phase II nonrandomized trial included 160 consecutive, previously untreated patients with MCL less than 66 years old treated with dose-intensified R-CHOP alternating with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      plus high dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      followed by high dose chemotherapy and autologous HCT in responders [",
"      <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/32\">",
"       32",
"      </a>",
"      ]. Rates of overall and complete response were 96 and 54 percent, respectively. In an intention-to-treat analysis with a median observation of 3.9 years, the four-year rates of event-free and overall survival were 63 and 81 percent, respectively. In a subsequent report of the same trial with a median observation of 6.5 years, the estimated 10-year event-free and overall survival rates were 43 and 58 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A single arm phase II study evaluated autologous HCT for 87 patients with newly diagnosed MCL up to 66 years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/60\">",
"       60",
"      </a>",
"      ]. Patients who had an at least partial initial response to three courses of R-CHOP chemotherapy were eligible to proceed with the HCT protocol that included consolidation with high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      followed by stem cell mobilization with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      , conditioning with BEAM, and infusion of autologous stem cells. The overall and complete response rates were 70 and 64 percent, respectively. Overall survival rates at four years were 66 and 79 percent for the group as a whole and those patients who had an at least partial response to R-CHOP, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    New induction regimens, including combinations of monoclonal antibodies and chemotherapy, followed by autologous or allogeneic HCT in first remission, may have an impact on the outcome of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/55,59,62-65\">",
"     55,59,62-65",
"    </a>",
"    ]. More extended follow-up of patients treated with these approaches, including the use of allogeneic HCT, will be required.",
"   </p>",
"   <p>",
"    As mentioned above, for young, fit patients, we suggest the use of conventional chemotherapy (eg, R-CHOP, R-CVP, BR) followed by high dose chemotherapy and autologous HCT (rescue) rather than conventional chemotherapy alone. The intensity of induction chemotherapy does not appear to affect outcomes following autologous HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/61\">",
"     61",
"    </a>",
"    ]. In contrast, we do not offer autologous HCT to patients who attain an initial response to induction with R-Hyper-CVAD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/29/30169?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of mantle cell lymphoma\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H247521636\">",
"    <span class=\"h1\">",
"     LONG-TERM MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H247521657\">",
"    <span class=\"h2\">",
"     Maintenance therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance therapy refers to the prolonged administration of agents with low toxicity profiles in an attempt to prevent progression of disease. Maintenance therapy is commonly employed in the management of other types of lymphoma, but the role of maintenance in mantle cell lymphoma is less well understood. Maintenance therapy improves progression-free survival (PFS) and may improve overall survival in a subset of patients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An international randomized trial compared maintenance",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      versus maintenance interferon-alfa in 316 older adults (&gt;60 years) with previously untreated MCL who achieved a complete or partial remission after initial rituximab-based combination chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/27\">",
"       27",
"      </a>",
"      ]. A subset analysis suggested a significant survival benefit from maintenance rituximab in patients who had initial treatment with R-CHOP (estimated overall survival rate at four years of 87 versus 63 percent).",
"     </li>",
"     <li>",
"      In a single institution pilot study, 22 patients were treated with modified R-HyperCVAD and maintenance",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      resulting in a median PFS of 38 months and a median overall survival of 70 months [",
"      <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/66\">",
"       66",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      A single institution retrospective analysis of 44 patients undergoing initial therapy with R-HyperCVAD reported longer median PFS among patients who underwent consolidative autologous hematopoietic cell transplantation (HCT, 17 patients, PFS 4.5 years) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      maintenance (12 patients; PFS 3.9 years) when compared with those observed until progression (15 patients; PFS 2.3 years) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/63/17402/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A decision regarding the use of maintenance therapy in an individual patient must take into consideration both the potential benefit from attaining a deeper response and the likelihood that this patient will tolerate the prolonged therapy. For patients with newly diagnosed MCL who have had at least a PR to conventional chemoimmunotherapy and do not plan to undergo autologous HCT, we suggest the use of maintenance",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    until progression rather than observation with treatment at the time of progression. This preference places a high value on a potential improvement in PFS while understanding that this choice may be associated with increased toxicity and a potentially impaired response to immunotherapy at the time of relapse. We do not routinely administer maintenance rituximab after autologous HCT or after induction with R-Hyper-CVAD.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    therapy does impose a risk of hepatitis B reactivation among patients positive for HBsAg or anti-HBc. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=see_link\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Surveillance for relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the completion of therapy, restaging, and documentation of complete remission, patients are seen at periodic intervals to monitor for treatment complications and assess for possible relapse. The frequency and extent of these visits depends upon the comfort of both the patient and physician. There have been no prospective, randomized trials comparing various schedules of follow-up. When planning the post-treatment surveillance strategy, care should be taken to limit the number of CT scans, particularly in younger individuals, given concerns about radiation exposure and the risk for second malignancies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=see_link\">",
"     \"Radiation-related risks of imaging studies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Our approach to patient surveillance is to schedule patient visits every two months during the first year, every three months during the second year, and every six months starting two years after complete response. At these visits we perform a history and physical examination, complete blood count, chemistries, and LDH. We typically perform CT scans every six months for the first three to five years of follow-up. This is principally because the majority of relapses occur in the first two to four years after treatment.",
"   </p>",
"   <p>",
"    Relapsed disease can be suggested by changes on imaging studies but can only be confirmed by biopsy. As such, a biopsy should always be obtained to document relapsed disease before proceeding to salvage therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1065?source=see_link\">",
"     \"Treatment of relapsed or refractory mantle cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mantle cell lymphoma (MCL) is an uncommon type of B cell non-Hodgkin lymphoma with a variable outcome. Combination chemotherapy plus immunotherapy (ie, chemoimmunotherapy) remains the main treatment modality with or without high dose therapy and autologous hematopoietic cell transplantation (HCT). Surgery is usually not of benefit, but may be of value in patients presenting with bowel obstruction. Likewise, radiation therapy is usually reserved for palliation. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Indications for treatment'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H5\">",
"     'Overview'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is a small subset of patients with MCL that will have a more indolent course and may not require treatment initially; however, the majority of patients will require treatment at the time of diagnosis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications for treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to a history and physical, the pretreatment evaluation includes, at minimum, laboratory studies (complete blood count with differential, chemistries with liver and renal function and electrolytes, lactate dehydrogenase, hepatitis B, HIV, and uric acid), computed tomography (CT), and bone marrow biopsy. Other studies are symptom or treatment specific. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pretreatment evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is a diversity of clinical practice and ambiguity surrounding the preferred treatment approach for patients with MCL. Whenever possible, young, otherwise healthy patients with advanced, symptomatic MCL should be referred to a center offering a",
"      <a class=\"external\" href=\"file://clinicaltrials.gov/\">",
"       clinical trial",
"      </a>",
"      . Outside of a clinical trial, a choice between treatment options depends upon patient characteristics such as age or comorbidities, patient preferences, side effect profiles, and the physician's comfort with the various regimens. The following are guidelines based upon our practice, which tends to favor the less aggressive treatment approaches; however, more aggressive treatment approaches used by other expert clinicians would also be acceptable.",
"     </li>",
"     <li>",
"      For all patients with MCL, we recommend the addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      to combination chemotherapy rather than chemotherapy alone (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Role for rituximab'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients, we suggest induction with conventional chemoimmunotherapy (eg, R-CHOP, R-CVP, BR) rather than more intensive chemoimmunotherapy (eg, R-Hyper-CVAD) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In general, we prefer R-CHOP (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      ) (",
"      <a class=\"graphic graphic_table graphicRef63586 \" href=\"UTD.htm?22/2/22574\">",
"       table 3",
"      </a>",
"      ) or BR (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/20/32071?source=see_link\">",
"       bendamustine",
"      </a>",
"      rituximab) based on their acceptable toxicity profile and our experience with these regimens. R-CVP (cyclophosphamide, vincristine, prednisone plus rituximab) is an acceptable alternative. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Conventional chemoimmunotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Disease response is determined by the International Workshop Criteria (",
"      <a class=\"graphic graphic_table graphicRef64921 \" href=\"UTD.htm?29/27/30140\">",
"       table 6",
"      </a>",
"      ) using information gathered from a history, physical examination, and CT scan obtained one month after completion of induction therapy. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Response evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with newly diagnosed MCL who have had at least a partial response to induction with conventional chemoimmunotherapy, we suggest consolidation with high dose therapy and autologous HCT (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In contrast, we do not offer autologous HCT to patients who choose more intensive chemoimmunotherapy, such as R-Hyper-CVAD. (See",
"      <a class=\"local\" href=\"#H1967069\">",
"       'Autologous transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with newly diagnosed MCL who have had at least a partial response to initial therapy and are not eligible for autologous HCT, we suggest the use of maintenance",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      until progression, rather than observation with treatment at the time of progression (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This preference places a high value on a potential improvement in PFS while understanding that this choice may be associated with increased toxicity and a potentially impaired response to immunotherapy at the time of relapse. We do not routinely administer maintenance rituximab after autologous HCT or R-Hyper-CVAD. (See",
"      <a class=\"local\" href=\"#H247521657\">",
"       'Maintenance therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surveillance for relapse is scheduled according to the comfort levels of both the patient and physician. Patients are followed with serial history, physical examination, laboratory evaluation (complete blood count, chemistries, and LDH), and imaging studies. Relapsed disease can be suggested by changes on imaging studies but can only be confirmed by biopsy. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Surveillance for relapse'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/1\">",
"      Yoong Y, Kurtin PJ, Allmer C, et al. Efficacy of splenectomy for patients with mantle cell non-Hodgkin's lymphoma. Leuk Lymphoma 2001; 42:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/2\">",
"      Angelopoulou MK, Siakantariz MP, Vassilakopoulos TP, et al. The splenic form of mantle cell lymphoma. Eur J Haematol 2002; 68:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/3\">",
"      Ruchlemer R, Wotherspoon AC, Thompson JN, et al. Splenectomy in mantle cell lymphoma with leukaemia: a comparison with chronic lymphocytic leukaemia. Br J Haematol 2002; 118:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/4\">",
"      Orchard J, Garand R, Davis Z, et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood 2003; 101:4975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/5\">",
"      Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 2009; 27:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/6\">",
"      Determann O, Hoster E, Ott G, et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 2008; 111:2385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/7\">",
"      Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008; 111:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/8\">",
"      Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007; 99:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/9\">",
"      Hosein PJ, Pastorini VH, Paes FM, et al. Utility of positron emission tomography scans in mantle cell lymphoma. Am J Hematol 2011; 86:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/10\">",
"      Bodet-Milin C, Touzeau C, Leux C, et al. Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group. Eur J Nucl Med Mol Imaging 2010; 37:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/11\">",
"      Mato AR, Svoboda J, Feldman T, et al. Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD. Cancer 2012; 118:3565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/12\">",
"      Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma. Blood 2007; 110:3507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/13\">",
"      Martin P, Chadburn A, Christos P, et al. Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. Ann Oncol 2008; 19:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/14\">",
"      Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000; 18:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/15\">",
"      Ghielmini M, Schmitz SF, Cogliatti S, et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005; 23:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/16\">",
"      Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005; 23:7013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/17\">",
"      Khouri IF, Romaguera J, Kantarjian H, et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998; 16:3803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/18\">",
"      Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005; 23:1984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/19\">",
"      Herold M, Haas A, Doerken B, et al. Immunochemotherapy (R-MCP) in advanced mantle cell lymphoma is not superior to chemotherapy (MCP) alone - 50 months up date of the OSHO phasae III study (abstract). Ann Oncol 2008; 19(suppl 4):12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/20\">",
"      Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104:3064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/21\">",
"      Andersen NS, Pedersen LB, Laurell A, et al. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J Clin Oncol 2009; 27:4365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/22\">",
"      Schulz H, Bohlius J, Skoetz N, et al. Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma. Cochrane Database Syst Rev 2007; :CD003805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/23\">",
"      Griffiths R, Mikhael J, Gleeson M, et al. Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma. Blood 2011; 118:4808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/24\">",
"      Meusers P, Engelhard M, Bartels H, et al. Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis. Hematol Oncol 1989; 7:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/25\">",
"      Nickenig C, Dreyling M, Hoster E, et al. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Cancer 2006; 107:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/26\">",
"      Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/27\">",
"      Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012; 367:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/28\">",
"      Ruan J, Martin P, Furman RR, et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 2011; 29:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/29\">",
"      Teodorovic I, Pittaluga S, Kluin-Nelemans JC, et al. Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1995; 13:2819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/30\">",
"      Delarue R, Haioun C, Ribrag V, et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. Blood 2013; 121:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/31\">",
"      Hermine O, Hoster E, Walewski J, et al. Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Increases Overall Survival When Compared to 6 Courses of CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT in Mantle Cell Lymphoma: Final Analysis of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net) (abstract 151). Blood 2012; 120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/32\">",
"      Geisler CH, Kolstad A, Laurell A, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008; 112:2687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/33\">",
"      Geisler CH, Kolstad A, Laurell A, et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol 2012; 158:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/34\">",
"      Damon LE, Johnson JL, Niedzwiecki D, et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol 2009; 27:6101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/35\">",
"      Schaffel R, Hedvat CV, Teruya-Feldstein J, et al. Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma. Ann Oncol 2010; 21:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/36\">",
"      Hermine O, Hoster E, Walewski J, et al. Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: Final analysis of the MCL younger trial of the European Mantle Cell Lymphoma Network (MCL net) (abstract 151). Blood 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/37\">",
"      Zucca E, Roggero E, Pinotti G, et al. Patterns of survival in mantle cell lymphoma. Ann Oncol 1995; 6:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/38\">",
"      Eve HE, Seymour JF, Rule SA. Impairment of peripheral blood stem-cell mobilisation in patients with mantle-cell lymphoma following primary treatment with fludarabine and cyclophosphamide +/- rituximab. Leuk Lymphoma 2009; 50:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/39\">",
"      Ganti AK, Bierman PJ, Lynch JC, et al. Hematopoietic stem cell transplantation in mantle cell lymphoma. Ann Oncol 2005; 16:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/40\">",
"      Sweetenham JW. Stem cell transplantation for mantle cell lymphoma: should it ever be used outside clinical trials? Bone Marrow Transplant 2001; 28:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/41\">",
"      Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/42\">",
"      Khouri IF, Saliba RM, Okoroji GJ, et al. Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score. Cancer 2003; 98:2630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/43\">",
"      Till BG, Gooley TA, Crawford N, et al. Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma. Leuk Lymphoma 2008; 49:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/44\">",
"      Romaguera JE, Fayad LE, Feng L, et al. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 2010; 150:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/45\">",
"      Merli F, Luminari S, Ilariucci F, et al. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. Br J Haematol 2012; 156:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/46\">",
"      Epner E, Unger JM, Miller TP, et al. A multi center trial of hyperCVAD + rituxan in patients with nely diagnosed mantle cell lymphoma (abstract). Blood 2007; 110:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/47\">",
"      Chang JE, Peterson C, Choi S, et al. VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study. Br J Haematol 2011; 155:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/48\">",
"      LaCasce AS, Vandergrift JL, Rodriguez MA, et al. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood 2012; 119:2093.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/50\">",
"      Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/51\">",
"      Smith MR, Li H, Gordon L, et al. Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499. J Clin Oncol 2012; 30:3119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/52\">",
"      Bernard M, Tsang RW, Le LW, et al. Limited-stage mantle cell lymphoma: treatment outcomes at the Princess Margaret Hospital. Leuk Lymphoma 2013; 54:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/53\">",
"      Ketterer N, Salles G, Espinouse D, et al. Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma. Ann Oncol 1997; 8:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/54\">",
"      Freedman AS, Neuberg D, Gribben JG, et al. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol 1998; 16:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/55\">",
"      Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005; 105:2677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/56\">",
"      Murali S, Winton E, Waller EK, et al. Long-term progression-free survival after early autologous transplantation for mantle-cell lymphoma. Bone Marrow Transplant 2008; 42:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/57\">",
"      Vandenberghe E, Ruiz de Elvira C, Loberiza FR, et al. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol 2003; 120:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/58\">",
"      Evens AM, Winter JN, Hou N, et al. A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma. Br J Haematol 2008; 140:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/59\">",
"      Gianni AM, Magni M, Martelli M, et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 2003; 102:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/60\">",
"      van 't Veer MB, de Jong D, MacKenzie M, et al. High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. Br J Haematol 2009; 144:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/61\">",
"      Budde LE, Guthrie KA, Till BG, et al. Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation. J Clin Oncol 2011; 29:3023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/62\">",
"      Magni M, Di Nicola M, Devizzi L, et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 2000; 96:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/63\">",
"      Mangel J, Buckstein R, Imrie K, et al. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma. Semin Oncol 2002; 29:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/64\">",
"      Thieblemont C, Antal D, Lacotte-Thierry L, et al. Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma. Cancer 2005; 104:1434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/65\">",
"      Tam CS, Bassett R, Ledesma C, et al. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 2009; 113:4144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/66\">",
"      Kenkre VP, Long WL, Eickhoff JC, et al. Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network. Leuk Lymphoma 2011; 52:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/63/17402/abstract/67\">",
"      Ahmadi T, McQuade J, Porter D, et al. Potential prolongation of PFS in mantle cell lymphoma after R-HyperCVAD: auto-SCT consolidation or rituximab maintenance. Bone Marrow Transplant 2012; 47:1082.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4719 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-41275854C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_63_17402=[""].join("\n");
var outline_f16_63_17402=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H413544\">",
"      ONCOLOGIC EMERGENCIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS FOR TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PRETREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INITIAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Role for rituximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1967967\">",
"      Induction chemoimmunotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Conventional chemoimmunotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Hyper-CVAD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4668248\">",
"      Our treatment approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      RESPONSE EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1966877\">",
"      CONSOLIDATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1967069\">",
"      Autologous transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H247521636\">",
"      LONG-TERM MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H247521657\">",
"      Maintenance therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Surveillance for relapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4719\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4719|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/59/37819\" title=\"table 1\">",
"      Ann Arbor system in lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/21/17757\" title=\"table 2\">",
"      Int prognostic index NHL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/2/22574\" title=\"table 3\">",
"      R-CHOP21 regimen for non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/12/39116\" title=\"table 4\">",
"      MIPI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/15/9467\" title=\"table 5\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/27/30140\" title=\"table 6\">",
"      NHL treatment response criteria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/29/30169?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of mantle cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=related_link\">",
"      Clinical presentation and diagnosis of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8714?source=related_link\">",
"      Clinical presentation and diagnosis of primary gastrointestinal lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/50/19241?source=related_link\">",
"      Determining eligibility for autologous hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=related_link\">",
"      Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=related_link\">",
"      Hepatitis B virus reactivation associated with immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/7/19576?source=related_link\">",
"      Hyperleukocytosis and leukostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=related_link\">",
"      Initial evaluation and staging of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9865?source=related_link\">",
"      Initial treatment of limited stage (I/II) follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3930?source=related_link\">",
"      Management of gastrointestinal lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29352?source=related_link\">",
"      Overview of the treatment of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=related_link\">",
"      Radiation-related risks of imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/38/8807?source=related_link\">",
"      Small bowel obstruction: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1065?source=related_link\">",
"      Treatment of relapsed or refractory mantle cell lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_63_17403="Antibiotics for lung abscess";
var content_f16_63_17403=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F64257&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F64257&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antibiotic selections in patients with anaerobic lung abscess",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Preferred",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Clindamycin or beta lactam-beta lactamase inhibitor combination drugs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Drugs with established merit from clinical trials",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Penicillin, tetracycline (data from 1950-1970)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Metronidazole plus penicillin (data from 1980-1990)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Drugs with good in vitro activity against anaerobes but minimal clinical data",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chloramphenicol, cefoxitin, cefotetan, moxifloxacin, piperacillin, imipenem, meropenem",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Drugs with variable activity against anaerobes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cephalosporins, tetracycline, macrolides, levofloxacin, penicillin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Drugs with virtually no activity against anaerobes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Aztreonam, trimethoprim-sulfamethoxazole, aminoglycosides, ciprofloxacin",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_63_17403=[""].join("\n");
var outline_f16_63_17403=null;
var title_f16_63_17404="Von Willebrand factor assays";
var content_f16_63_17404=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F73391&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F73391&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Terminology - von Willebrand factor",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Designation",
"      </td>",
"      <td class=\"subtitle1\">",
"       Function",
"      </td>",
"      <td class=\"subtitle1\">",
"       Assay",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Von Willebrand factor (VWF)",
"      </td>",
"      <td>",
"       Multimeric glycoprotein that promotes platelet adhesion and aggregation and is a carrier for factor VIII in plasma",
"      </td>",
"      <td>",
"       See below",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"3\">",
"       Von Willebrand factor activity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       1 - von Willebrand factor: ristocetin cofactor (VWF:RCo)",
"      </td>",
"      <td class=\"sublist_other\">",
"       Ability of VWF to bind to normal platelets in the presence of ristocetin with consequent agglutination",
"      </td>",
"      <td class=\"sublist_other\">",
"       Quantitate platelet agglutination/aggregation after addition of ristocetin and VWF (patient plasma)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       2 - von Willebrand factor: collagen binding (VWF:CB)",
"      </td>",
"      <td class=\"sublist_other\">",
"       Ability of VWF to bind to collagen",
"      </td>",
"      <td class=\"sublist_other\">",
"       Quantitate binding of VWF (patient plasma) to collagen-coated plates",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Von Willebrand factor antigen (VWF:Ag)",
"      </td>",
"      <td>",
"       VWF protein as measured by immunologic assays; does not imply functional ability",
"      </td>",
"      <td>",
"       Immunologic assay such as ELISA, RIA, or Laurell electroimmunoassay",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Von Willebrand factor multimers",
"      </td>",
"      <td>",
"       Size distribution of VWF multimers as assessed by agarose gel electrophoresis",
"      </td>",
"      <td>",
"       Electrophoresis in low concentration agarose gel and visualization by monospecific antibody to VWF",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ristocetin-induced platelet aggregation (RIPA)",
"      </td>",
"      <td>",
"       Ability of patient's VWF to bind to platelets in the presence of suboptimal concentrations of ristocetin",
"      </td>",
"      <td>",
"       Platelet aggregation using patient's platelet-rich plasma and lower concentrations of ristocetin than VWF:RCo",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       VWF activity/antigen ratio (VWF:Act/Ag)",
"      </td>",
"      <td>",
"       Compare functional activity of VWF with its protein concentration",
"      </td>",
"      <td>",
"       Ratio of measured levels of VWF:RCo to VWF:Ag",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: The National Heart, Lung, and Blood Institute. The Diagnosis, Evaluation, and Management of Von Willebrand Disease. Bethesda, MD: National Institutes of Health Publication 08-5832, December 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_63_17404=[""].join("\n");
var outline_f16_63_17404=null;
var title_f16_63_17405="DDx vomiting infants";
var content_f16_63_17405=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61133&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61133&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of vomiting in infants",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tr>",
"          <td class=\"subtitle1_single\">",
"           Gastrointestinal obstruction",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Pyloric stenosis",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Malrotation with volvulus",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Intussusception (may be intermittent)",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Intestinal duplication, stenosis, or atresia",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Hirschsprung disease",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Antral/duodenal web",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Foreign body",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Incarcerated hernia",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"subtitle1_single\">",
"           Other gastrointestinal causes",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Physiological gastroesophageal reflux or GERD",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Food allergy or intolerance",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Gastroenteritis",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Peptic ulcer disease",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Eosinophilic esophagitis/gastroenteritis",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Gastroparesis",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Pancreatitis",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"subtitle1_single\">",
"           Neurologic",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Hydrocephalus",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Subdural hematoma",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Intracranial hemorrhage",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Mass lesion",
"          </td>",
"         </tr>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tr>",
"          <td class=\"subtitle1_single\">",
"           Infectious",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Sepsis",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Meningitis",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Urinary tract infection",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Pneumonia",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Otitis media",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Hepatitis",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"subtitle1_single\">",
"           Metabolic/endocrine",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Galactosemia",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Hereditary fructose intolerance",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Urea cycle defects",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Amino and organic acidemias",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Fatty acid oxidation disorders",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Metabolic acidosis",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Congenital adrenal hyperplasia/adrenal crisis",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"subtitle1_single\">",
"           Renal",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Obstructive uropathy",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Renal insufficiency",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"subtitle1_single\">",
"           Toxic",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Lead",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Iron",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Vitamin A or D",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Medications (ipecac, digoxin, theophylline, etc)",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Other toxins",
"          </td>",
"         </tr>",
"         <tr>",
"          <td class=\"subtitle1_single\">",
"           Cardiac",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Heart failure",
"          </td>",
"         </tr>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Rudolph CD, Mazur LJ, Liptak GS, et al. Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children: recommendations of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 2001; 32:S1. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_63_17405=[""].join("\n");
var outline_f16_63_17405=null;
var title_f16_63_17406="Contents: Diagnostic issues rheumatology";
var content_f16_63_17406=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?3/39/3710\">",
"       Rheumatology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Diagnostic issues rheumatology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Diagnostic issues rheumatology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Autoantibodies",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/43/2743\">",
"           Anti-U1 RNP antibodies in mixed connective tissue disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/10/1192\">",
"           Antibodies to double-stranded (ds)DNA, Sm, and U1 RNP",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/4/27718\">",
"           Antiribosomal P protein antibodies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/54/28520\">",
"           Measurement and clinical significance of antinuclear antibodies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/44/42695\">",
"           Miscellaneous antinuclear antibodies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/41/42648\">",
"           Origin and utility of measurement of rheumatoid factors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/23/8568\">",
"           The anti-Ro/SSA and anti-La/SSB antigen-antibody systems",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cryoproteins",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/25/7576\">",
"           Cryofibrinogenemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/63/22522\">",
"           Overview of cryoglobulins and cryoglobulinemia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Evaluation of rheumatic complaints",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/14/28904\">",
"           Evaluation of the adult with monoarticular pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/15/34039\">",
"           Evaluation of the adult with polyarticular pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/17/25879\">",
"           Evaluation of the patient with hand pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/35/15929\">",
"           Preoperative evaluation and perioperative management of patients with rheumatic diseases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/56/20360\">",
"           Synovial fluid analysis and the diagnosis of septic arthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/61/42968\">",
"           Undifferentiated systemic rheumatic (connective tissue) diseases and overlap syndromes",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Imaging",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/18/4392\">",
"           Musculoskeletal ultrasonography: Clinical applications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/31/44536\">",
"           Musculoskeletal ultrasonography: Guided injection and aspiration of joints and related structures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/60/1991\">",
"           Musculoskeletal ultrasonography: Nomenclature, technical considerations, validation, and standardization",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/21/31063\">",
"           Radiologic evaluation of knee tumors in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/12/12489\">",
"           Radiologic evaluation of the acutely painful knee in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/50/25385\">",
"           Radiologic evaluation of the chronically painful knee in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/39/25210\">",
"           Radiologic evaluation of the painful hip in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/36/36425\">",
"           Radiologic evaluation of the painful shoulder",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Joint aspiration",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/14/30951\">",
"           Intraarticular and soft tissue injections: What agent(s) to inject and how frequently?",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/57/28564\">",
"           Joint aspiration or injection in adults: Complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/52/23368\">",
"           Joint aspiration or injection in adults: Technique and indications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/56/20360\">",
"           Synovial fluid analysis and the diagnosis of septic arthritis",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-988086C642-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f16_63_17406=[""].join("\n");
var outline_f16_63_17406=null;
var title_f16_63_17407="Subacromial bursa injection in children";
var content_f16_63_17407=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F51897&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F51897&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Subacromial bursa injection in children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 339px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The lateral or posterior approach can be used to inject the subacromial bursa; the lateral approach shown here is safer to perform, since injection into the rotator cuff tendons is nearly impossible with this technique. The patient is to be sitting up, with the hands placed in the lap. The patient is asked to relax the shoulder and neck muscles. Traction applied to the flexed elbow may be necessary to open the subacromial space. The lateral edge of the acromion is located and its midpoint marked. The point of entry is 1 to 1 1/2\" below the marked midpoint. The angle of entry should parallel the patient's own acromial angle (averaging 50- to 65-degrees). The depth will vary according to the patient's weight and muscle development (1 1/2\" in an asthenic patient and up to 3 1/2\" in an obese patient over 30 percent ideal body weight). Ethyl chloride is sprayed on the skin. Local anesthetic is placed in the deltoid muscle (1 mL) and the deep deltoid fascia (0.5 mL). The needle is advanced through the subcutaneous tissue and the deltoid muscle until the subtle resistance of the deep deltoid fascia is encountered. If firm or hard tissue resistance is encountered (deltoid tendon or periosteum, often painful), then the needle is withdrawn 1/2\" and the angle is redirected 5- to 10-degrees either up or down. A \"giving way\" or \"popping\" sensation is often appreciated when the subacromial bursa is entered. Following 1 to 2 mL of anesthesia and leaving the needle in position, the patient strength is tested again. If pain is reduced by 50 percent and the strength of abduction and external rotation are 75 to 80 percent of the unaffected side, then triamcinolone acetonide (1 mg/kg of 40 mg/mL suspension, maximum 40 mg) is injected. Note, never inject under moderate to high pressure. If high injection pressure is encountered, first try rotating the syringe 180 degrees. If tension is still high and the patient obviously anxious, ask the patient to take a deep breath and try to relax the shoulder muscles. If tension remains high, reposition the needle by 1/4\" increments or by altering the angle of entry by 5- to 10-degrees. The subacromial bursa will accept only 2 to 3 mL of total volume before rupturing.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_63_17407=[""].join("\n");
var outline_f16_63_17407=null;
